

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031775 A2

(51) International Patent Classification⁷: **G01N 33/574**,
A61K 39/00, C12Q 1/68, A61P 35/04, C12N 15/11, C07K
16/30, 14/47

(21) International Application Number:
PCT/JP2003/010339

(22) International Filing Date: 14 August 2003 (14.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/414,709 30 September 2002 (30.09.2002) US

(71) Applicants (for all designated States except US): **ONCOTHERAPY SCIENCE, INC.** [JP/JP]; 3-16-13, Shirokanedai, Minato-ku, Tokyo 108-0071 (JP). **JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO** [JP/JP]; 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 113-8654 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NAKAMURA, Yusuke** [JP/JP]; 17-33, Azamino 1-chome, Aoba-ku, Yokohama-shi, Kanagawa 225-0011 (JP). **FURUKAWA, Yoichi** [JP/JP]; 10-40, Miyazaki 3-chome, Miyamae-ku, Kawasaki-shi, Kanagawa 216-0033 (JP).

(74) Agents: **SHIMIZU, Hatsushi** et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki 300-0847 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR TREATING OR PREVENTING METASTASIS OF COLORECTAL CANCERS

(57) Abstract: Disclosed are methods of identifying agents for treating metastatic lesions of colorectal cancer. Also disclosed are methods for treating metastatic lesions of colorectal cancer and preventing metastasis of colorectal cancer.

WO 2004/031775 A2

DESCRIPTIONMETHOD FOR TREATING OR PREVENTING METASTASIS OF COLORECTAL
CANCERS

5 The present application is related to USSN 60/414,709, filed September 30, 2002,
which is incorporated herein by reference.

Technical Field

10 The invention relates to methods of treating metastatic lesions of colorectal cancers
and preventing metastasis of colorectal cancers.

Background Art

15 Liver metastasis is a major cause of death among patients with colorectal cancer
(CRC). Despite progress that has been achieved with therapeutic approaches, a complete
cure awaits more effecting strategies. Prevention or effective treatment of liver metastasis
will save the lives of thousands of patients.

20 The process of metastasis involves multiple steps that include release of cancer
cells from the primary site, intravasation to neighboring vessels, transport to the site of
metastasis through blood flow, extravasation and/or infarction to the distant organ, and
re-growth of the invading cells with acquisition of nutrition in the new environment.
Therefore multiple genes are expected to be associated with the process of metastasis.
Although many investigators have been working on this clinically important issue, the
precise mechanisms or identification of the critical genes remain to be clarified. A
number of molecules associated with liver metastasis have been reported, but as most
25 studies have focused on only one or a few molecules, the importance of each genes in the
complex process remains obscure.

30 Due to the progress in microarray technology, expression levels of thousands of
genes can be identified in a single experiment and classification of cancer based on altered
expression of multiple genes in tumor tissues is suggested (Golub et al., Science 286:
531-7 (1999); Alizadeh et al., Nature 403: 503-11 (2000)). cDNA microarray
technologies have enabled to obtain comprehensive profiles of gene expression in normal
and malignant cells, and compare the gene expression in malignant and corresponding
normal cells (Okabe et al., Cancer Res 61:2129-37 (2001); Kitahara et al., Cancer Res 61:
3544-9 (2001); Lin et al., Oncogene 21:4120-8 (2002); Hasegawa et al., Cancer Res
35 62:7012-7 (2002)). This approach enables to disclose the complex nature of cancer cells,
and helps to understand the mechanism of carcinogenesis as well as metastasis of cancer.

Identification of genes that are deregulated in tumors can lead to more precise and accurate diagnosis of individual cancers, and to develop novel therapeutic targets (Bienz and Clevers, Cell 103:311-20 (2000)).

5 Recently two groups detected genes responsible for metastasis of malignant melanomas, using cDNA microarrays. One group compared the expression profiles of highly metastatic melanoma cells with less metastatic cells, established from the same cell lines (Clark et al., Nature 406: 532-5 (2000)). On the other hand, the other group analyzed expression profiles among various melanoma cell lines and primary melanomas (Bittner et al., Nature 406: 536-40 (2000)). Furthermore, to disclose the mechanisms
10 underlying liver metastasis of colorectal cancer, the present inventors previously analyzed expression profiles of 10 primary tumors and their corresponding metastatic lesions using a cDNA microarray containing 9121 genes (Yanagawa et al., Neoplasia 3: 395-401 (2001)).

Studies designed to reveal mechanisms of carcinogenesis have already facilitated identification of molecular targets for anti-tumor agents. Various agents designed to
15 suppress oncogenic activity of specific gene products have been revealed to be effective for treating tumors (He et al., Cell 99:335-45 (1999); Lin et al., Cancer Res 61:6345-9 (2001); Fujita et al., Cancer Res 61:7722-6 (2001)). Therefore, gene products commonly up-regulated in cancerous cells may serve as potential targets for developing novel anti-cancer agents.

20 CD8+ cytotoxic T lymphocytes (CTLs) have been demonstrated to recognize epitope peptides derived from tumor-associated antigens (TAAs) presented on MHC Class I molecule, and lyse tumor cells. Since the discovery of MAGE family as the first example of TAAs, many other TAAs have been discovered using immunological approaches (Boon, Int J Cancer 54: 177-80 (1993); Boon and van der Bruggen, J Exp Med
25 183: 725-9 (1996); van der Bruggen et al., Science 254: 1643-7 (1991); Brichard et al., J Exp Med 178: 489-95 (1993); Kawakami et al., J Exp Med 180: 347-52 (1994)). Some of the discovered TAAs are now at the stage of clinical development as targets of immunotherapy. TAAs discovered so far include MAGE (van der Bruggen et al., Science 254: 1643-7 (1991)), gp100 (Kawakami et al., J Exp Med 180: 347-52 (1994)), SART
30 (Shichijo et al., J Exp Med 187: 277-88 (1998)) and NY-ESO-1 (Chen et al., Proc Natl Acad Sci USA 94: 1914-8 (1997)). On the other hand, gene products which had been demonstrated to be specifically overexpressed in tumor cells, have been shown to be recognized as targets inducing cellular immune responses. Such gene products include
35 p53 (Umamo et al., Brit J Cancer 84: 1052-7 (2001)), HER2/neu (Tanaka et al., Brit J Cancer 84: 94-9 (2001)), CEA (Nukaya et al., Int J Cancer 80: 92-7 (1999)), and so on.

In spite of significant progress in basic and clinical research concerning TAAs

(Rosenbeg et al., Nature Med 4: 321-7 (1998); Mukherji et al., Proc Natl Acad Sci USA 92: 8078-82 (1995); Hu et al., Cancer Res 56: 2479-83 (1996)), only limited number of candidate TAAs for the treatment of adenocarcinomas, including colorectal cancer, are available. TAAs abundantly expressed in cancer cells, and at the same time which expression is restricted to cancer cells would be promising candidates as immunotherapeutic targets. Further, identification of new TAAs inducing potent and specific antitumor immune responses is expected to encourage clinical use of peptide vaccination strategy in various types of cancer (Boon and van der Bruggen, J Exp Med 183: 725-9 (1996); van der Bruggen et al., Science 254: 1643-7 (1991); Brichard et al., J Exp Med 178: 489-95 (1993); Kawakami et al., J Exp Med 180: 347-52 (1994); Shichijo et al., J Exp Med 187: 277-88 (1998); Chen et al., Proc Natl Acad Sci USA 94: 1914-8 (1997); Harris, J Natl Cancer Inst 88: 1442-5 (1996); Butterfield et al., Cancer Res 59: 3134-42 (1999); Vissers et al., Cancer Res 59: 5554-9 (1999); van der Burg et al., J Immunol 156: 3308-14 (1996); Tanaka et al., Cancer Res 57: 4465-8 (1997); Fujie et al., Int J Cancer 80: 169-72 (1999); Kikuchi et al., Int J Cancer 81: 459-66 (1999); Oiso et al., Int J Cancer 81: 387-94 (1999)).

Summary of the Invention

The present invention is based on the discovery of a pattern of gene expression correlated with metastatic lesions of colorectal cancer.

Accordingly, the present invention features a method of screening for a compound for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer. The method includes contacting a MLX polypeptide with a test compound, and selecting the test compound that bind to the MLX polypeptide.

Furthermore, the present invention provides a method of screening for a compound for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer, wherein the method includes contacting a MLX polypeptide with a test compound, and selecting a compound that suppresses the biological activity of the MLX polypeptide.

The present invention further provides a method of screening for a compound for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer, wherein the method includes contacting a cell expressing one or more of the MLX polypeptides with a test compound, and selecting the test compound that suppresses the expression level of one or more MLX polypeptides.

Furthermore, the present invention provides a method of screening for a compound for treating colorectal cancer or preventing metastasis of colorectal cancer, wherein the method includes contacting a test compound and a vector comprising a reporter gene

downstream of a transcriptional regulatory region of MLX genes under a suitable condition for the expression of the reporter gene, and selecting the test compound that inhibits the expression of the reporter gene.

The present application also provides a composition for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer. The composition may be, for example, an anti-cancer agent. The composition can be described as at least a portion of the antisense S-oligonucleotides or small interfering RNA (siRNA) of the MLX polynucleotides or antibody or fragment of the antibody against the MLX proteins. The compositions may be also those comprising the compounds selected by the present methods of screening for compounds for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer.

The course of action of the pharmaceutical composition is desirably to inhibit growth or proliferation of the metastatic lesion of colorectal cancer. The pharmaceutical composition may be applied to mammals including humans and domesticated mammals.

Furthermore, the present invention provides a composition for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer comprising an MLX protein, a polynucleotide encoding the protein or a vector comprising the polynucleotide. Such compositions are expected to induce anti-tumor immunity.

The present invention further provides methods for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer using any of the compositions provided by the present invention.

The invention also provides a kit with a detection reagent which binds to one or more MLX nucleic acid sequences or which binds to a gene product encoded by the nucleic acid sequences. Also provided is an array of nucleic acids that binds to one or more MLX nucleic acids. Such kits and arrays are expected to be useful for diagnosing metastasis of colorectal cancer.

It is to be understood that both the foregoing summary of the invention and the following detailed description are of a preferred embodiment, and not restrictive of the invention or other alternate embodiments of the invention.

Detailed Description of the Invention

The words "a", "an", and "the" as used herein mean "at least one" unless otherwise specifically indicated.

The present invention is based in part on the discovery of changes (increase) in expression patterns of multiple nucleic acid sequences in metastatic lesion compared to corresponding primary lesions of patients with colorectal cancer with metastasis. The

differences in gene expression were identified using laser-capture microdissection (LCM) and a comprehensive cDNA microarray system. The differentially expressed genes identified herein are used for developing gene targeted therapeutic approaches to treat colorectal cancer, especially metastatic lesions of colorectal cancer, and to inhibit metastasis of colorectal cancer.

The genes whose expression levels are increased in metastatic lesions of patients suffering from colorectal cancer are summarized in Table 1 and are collectively referred to herein as "metastasis-associated genes", "MLX nucleic acids" or "MLX polynucleotides" and the corresponding encoded polypeptides are referred to as "MLX polypeptides" or "MLX proteins". Unless indicated otherwise, "MLX" is meant to refer to any of the sequences disclosed herein (*e.g.*, MLX 1-153). The genes have been previously described and are presented along with a database accession number.

By measuring the expression of these genes or activity of protein encoded by the genes in response to various agents, agents for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer can be identified.

Screening compounds for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer

The present invention provides a method of screening for a compound for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer using one or more MLX polypeptides. An embodiment of this screening method comprises the steps of: (a) contacting a test compound with an MLX polypeptide, (b) detecting the binding activity between the polypeptide and the test compound, and (c) selecting a compound that binds to the MLX polypeptide.

In another embodiment of the method for screening a compound for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer of the present invention, the method utilizes the biological activity of the MLX polypeptide as an index. This screening method includes the steps of: (a) contacting a test compound with the MLX polypeptide; (b) detecting the biological activity of the MLX polypeptide of step (a); and (c) selecting a compound that suppresses the biological activity of the MLX polypeptide in comparison with the biological activity detected in the absence of the test compound.

The MLX polypeptide of the present invention used for the screening are selected from following polypeptides:

(1) a polypeptide comprising the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153;

(2) a polypeptide that comprises the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153, in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence encoded by the polynucleotide; and

- 5 (3) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide selected from the group consisting of MLXs 1-153, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence encoded by the polynucleotide selected from the group consisting of MLXs 1-153.

10 In the present invention, the term "biological activity" refers to activities such as growth or proliferation of metastatic lesions. Whether the subject polypeptide has the biological activity or not can be judged by introducing the DNA encoding the subject polypeptide into a cell expressing the respective polypeptide, and detecting growth or proliferation of the cells, increase in colony forming activity, etc.

15 Methods for preparing polypeptides having the biological activity of a given protein are well known by a person skilled in the art and include known methods of introducing mutations into the protein. For example, one skilled in the art can prepare polypeptides having the biological activity of the human MLX protein by introducing an appropriate mutation in the amino acid sequence of either of these proteins by site-directed
20 mutagenesis (Hashimoto-Gotoh et al., Gene 152:271-5 (1995); Zoller and Smith, Methods Enzymol 100: 468-500 (1983); Kramer et al., Nucleic Acids Res. 12:9441-9456 (1984); Kramer and Fritz, Methods Enzymol 154: 350-67 (1987); Kunkel, Proc Natl Acad Sci USA 82: 488-92 (1985); Kunkel, Methods Enzymol 85: 2763-6 (1988)). Amino acid mutations can occur in nature, too. The MLX polypeptide includes those proteins having the amino
25 acid sequences of the human MLX protein in which one or more amino acids are mutated, provided the resulting mutated polypeptides have the biological activity of the human MLX protein. The number of amino acids to be mutated in such a mutant is generally 10 amino acids or less, preferably 6 amino acids or less, and more preferably 3 amino acids or less.

30 Mutated or modified proteins, proteins having amino acid sequences modified by substituting, deleting, inserting, and/or adding one or more amino acid residues of a certain amino acid sequence, have been known to retain the original biological activity (Mark et al., Proc Natl Acad Sci USA 81: 5662-6 (1984); Zoller and Smith, Nucleic Acids Res 10:6487-500 (1982); Dalbadie-McFarland et al., Proc Natl Acad Sci USA 79: 6409-13
35 (1982)).

The amino acid residue to be mutated is preferably mutated into a different amino

acid in which the properties of the amino acid side-chain are conserved (a process known as conservative amino acid substitution). Examples of properties of amino acid side chains are hydrophobic amino acids (A, I, L, M, F, P, W, Y, V), hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, T), and side chains having the following functional groups or characteristics in common: an aliphatic side-chain (G, A, V, L, I, P); a hydroxyl group
5 containing side-chain (S, T, Y); a sulfur atom containing side-chain (C, M); a carboxylic acid and amide containing side-chain (D, N, E, Q); a base containing side-chain (R, K, H); and an aromatic containing side-chain (H, F, Y, W). Note, the parenthetic letters indicate the one-letter codes of amino acids.

10 An example of a polypeptide to which one or more amino acids residues are added to the amino acid sequence of human MLX protein is a fusion protein containing the human MLX protein. Fusion proteins are, fusions of the human MLX protein and other peptides or proteins, and are included in the MLX protein described herein. Fusion proteins can be made by techniques well known to a person skilled in the art, such as by
15 linking the DNA encoding the human MLX protein with DNA encoding other peptides or proteins, so that the frames match, inserting the fusion DNA into an expression vector and expressing it in a host. There is no restriction as to the peptides or proteins fused to the MLX protein.

Known peptides that can be used as peptides that are fused to the MLX protein
20 include, for example, FLAG (Hopp et al., Biotechnology 6: 1204-10 (1988)), 6xHis containing six His (histidine) residues, 10xHis, Influenza agglutinin (HA), human c-myc fragment, VSP-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40T antigen fragment, lck tag, α -tubulin fragment, B-tag, Protein C fragment, and the like. Examples of proteins that may be fused to an MLX protein include GST (glutathione-S-transferase),
25 Influenza agglutinin (HA), immunoglobulin constant region, β -galactosidase, MBP (maltose-binding protein), and such.

Fusion proteins can be prepared by fusing commercially available DNA, encoding the fusion peptides or proteins discussed above, with the DNA encoding the MLX polypeptide and expressing the fused DNA prepared. A commercially available
30 epitope-antibody system can be used (Experimental Medicine 13: 85-90 (1995)) for expressing such fusion proteins. Vectors which can express a fusion protein with, for example, β -galactosidase, maltose binding protein, glutathione S-transferase, green fluorescence protein (GFP) and so on by the use of its multiple cloning sites are commercially available.

35 An alternative method known in the art to isolate polypeptides having the biological activity of any of the MLX proteins is, for example, the method using a

hybridization technique (Sambrook et al., Molecular Cloning 2nd ed. 9.47-9.58, Cold Spring Harbor Lab. Press (1989)). One skilled in the art can readily isolate a DNA having high homology with a whole or part of the DNA sequence encoding the human MLX protein, and isolate polypeptides having the biological activity of the human MLX protein from the isolated DNA. The MLX polypeptides include those that are encoded by DNA that hybridize with a whole or part of the DNA sequence encoding the human MLX protein and have the biological activity of the human MLX protein. These polypeptides include mammal homologues corresponding to the protein derived from human (for example, a polypeptide encoded by a monkey, rat, rabbit and bovine gene). In isolating a cDNA highly homologous to the DNA encoding the human MLX protein from animals, it is particularly preferable to use metastatic lesions of colorectal cancers.

The condition of hybridization for isolating a DNA encoding a polypeptide having the biological activity of the human MLX protein can be routinely selected by a person skilled in the art. For example, hybridization may be performed by conducting prehybridization at 68°C for 30 min or longer using "Rapid-hyb buffer" (Amersham LIFE SCIENCE), adding a labeled probe, and warming at 68°C for 1 hour or longer. The following washing step can be conducted, for example, in a low stringent condition. A low stringent condition is, for example, 42°C, 2X SSC, 0.1% SDS, or preferably 50°C, 2X SSC, 0.1% SDS. More preferably, high stringent conditions are used. A high stringent condition is, for example, washing 3 times in 2X SSC, 0.01% SDS at room temperature for 20 min, then washing 3 times in 1x SSC, 0.1% SDS at 37°C for 20 min, and washing twice in 1x SSC, 0.1% SDS at 50°C for 20 min. However, several factors, such as temperature and salt concentration, can influence the stringency of hybridization and one skilled in the art can suitably select the factors to achieve the requisite stringency.

In place of hybridization, a gene amplification method, for example, the polymerase chain reaction (PCR) method, can be utilized to isolate a DNA encoding a polypeptide having the biological activity of the human MLX protein, using a primer synthesized based on the sequence information of the protein encoding DNA.

Polypeptides that have the biological activity of the human MLX protein encoded by the DNA isolated through the above hybridization techniques or gene amplification techniques, normally have a high homology to the amino acid sequence of the human MLX protein. "High homology" typically refers to a homology of 40% or higher, preferably 60% or higher, more preferably 80% or higher, even more preferably 95% or higher. The homology of a polypeptide can be determined by following the algorithm in "Wilbur and Lipman, Proc Natl Acad Sci USA 80: 726-30 (1983)".

An MLX polypeptide used in the method of the present invention may have

variations in amino acid sequence, molecular weight, isoelectric point, the presence or absence of sugar chains, or form, depending on the cell or host used to produce it or the purification method utilized. Nevertheless, so long as it has a biological activity equivalent to that of the human MLX protein, it may be used in the method of the present invention and such methods utilizing polypeptides with a biological activity equivalent to the MXL protein are within the scope of the present invention.

The MLX polypeptides used in the present invention can be prepared as recombinant proteins or natural proteins, by methods well known to those skilled in the art. A recombinant protein can be prepared by inserting a DNA, which encodes the MLX polypeptide, into an appropriate expression vector, introducing the vector into an appropriate host cell, obtaining the extract, and purifying the polypeptide.

Specifically, when *E. coli* is used as a host cell to prepare an MLX polypeptide, the vector should have "ori" to be amplified in *E. coli* and a marker gene for selecting transformed *E. coli* (e.g., a drug-resistance gene selected by a drug such as ampicillin, tetracycline, kanamycin, chloramphenicol or the like). In addition, the expression vector to be expressed in *E. coli* should have a promoter, for example, lacZ promoter (Ward et al., Nature 341: 544-6 (1989); FASEB J 6: 2422-7 (1992)), araB promoter (Better et al., Science 240: 1041-3 (1988)), or T7 promoter or the like, that can efficiently express the desired gene in *E. coli*. In that respect, pGEX-5X-1 (Pharmacia), "QIAexpress system" (Qiagen), pEGFP and pET (in this case, the host is preferably BL21 which expresses T7 RNA polymerase), for example, can be used instead of the above vectors. Additionally, the vector may also contain a signal sequence for polypeptide secretion. An exemplary signal sequence that directs the polypeptide to be secreted to the periplasm of the *E. coli* is the pelB signal sequence (Lei et al., J Bacteriol 169: 4379 (1987)). Means for introducing of the vectors into the target host cells include, for example, the calcium chloride method, and the electroporation method.

In addition to *E. coli*, for example, expression vectors derived from mammals (for example, pcDNA3 (Invitrogen) and pEGF-BOS (Nucleic Acids Res 18(17): 5322 (1990)), pEF, pCDM8), expression vectors derived from insect cells (for example, "Bac-to-BAC baculovirus expression system" (GIBCO BRL), pBacPAK8), expression vectors derived from plants (e.g., pMH1, pMH2), expression vectors derived from animal viruses (e.g., pHSV, pMV, pAdexLcw), expression vectors derived from retroviruses (e.g., pZIpneo), expression vector derived from yeast (e.g., "Pichia Expression Kit" (Invitrogen), pNV11, SP-Q01), and expression vectors derived from *Bacillus subtilis* (e.g., pPL608, pKTH50) can be used for producing the MLX polypeptide.

In order to express the vector in animal cells, such as CHO, COS, or NIH3T3 cells,

the vector should have a promoter necessary for expression in such cells, for example, the SV40 early promoter (Rigby in Williamson (ed.), Genetic Engineering, vol. 3: Academic Press, London, 83-141 (1982)), the MMLV-LTR promoter, the EF1 α promoter (Mizushima et al., Nucleic Acids Res 18: 5322 (1990); Kim et al., Gene 91: 217-23 (1990)), the CAG promoter (Niwa et al., Gene 108: 193-200 (1991)), the RSV LTR promoter (Cullen, Methods in Enzymology 152: 684-704 (1987)), the SR α promoter (Takebe et al., Mol Cell Biol 8: 466 (1988)), the CMV immediate early promoter (Seed and Aruffo, Proc Natl Acad Sci USA 84: 3365-9 (1987)), the SV40 late promoter (Gheysen and Fiers, J Mol Appl Genet 1: 385-94 (1982)), the Adenovirus late promoter (Kaufman et al., Mol Cell Biol 9: 946 (1989)), the HSV TK promoter and the like, and preferably a marker gene for selecting transformants (for example, a drug resistance gene selected by a drug (e.g., neomycin, G418)). Examples of known vectors with these characteristics include, for example, pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13. The introduction of the gene into animal cells to express a foreign gene can be performed according to any methods, for example, the electroporation method (Chu et al., Nucleic Acids Res 15: 1311-26 (1987)), the calcium phosphate method (Chen and Okayama, Mol Cell Biol 7: 2745-52 (1987)), the DEAE dextran method (Lopata et al., Nucleic Acids Res 12: 5707-17 (1984); Sussman and Milman, Mol Cell Biol 4: 1642-3 (1985)), the Lipofectin method (Derijard, B Cell 7: 1025-37 (1994); Lamb et al., Nature Genetics 5: 22-30 (1993); Rabindran et al., Science 259: 230-4 (1993)), and so on.

In addition, methods may be used to express a gene stably and, at the same time, to amplify the copy number of the gene in cells. For example, a vector comprising the complementary DHFR gene (e.g., pCHO I) may be introduced into CHO cells in which the nucleic acid synthesizing pathway is deleted, and then amplified by methotrexate (MTX). Furthermore, in case of transient expression of a gene, the method wherein a vector comprising a replication origin of SV40 (pcD, etc.) is transformed into COS cells comprising the SV40 T antigen expressing gene on the chromosome can be used.

An MLX polypeptide obtained as above may be isolated from inside or outside (such as medium) of host cells, and purified as a substantially pure homogeneous polypeptide. The term "substantially pure" as used herein in reference to a given polypeptide means that the polypeptide is substantially free from other biological macromolecules. The substantially pure polypeptide is at least 75% (e.g., at least 80, 85, 95, or 99%) pure by dry weight. Purity can be measured by any appropriate standard method, for example by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. The method for polypeptide isolation and purification is not limited to any specific method; in fact, any standard method may be used.

For instance, column chromatography, filter, ultrafiltration, salt precipitation, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric point electrophoresis, dialysis, and recrystallization may be appropriately selected and combined to isolate and purify the polypeptide.

Examples of chromatography include, for example, affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, adsorption chromatography, and such (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed. Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press (1996)). These chromatographies may be performed by liquid chromatography, such as HPLC and FPLC.

Also when the MLX polypeptide is expressed within host cells (for example, animal cells and *E. coli*) as a fusion protein with glutathione-S-transferase protein or as a recombinant protein supplemented with multiple histidines, the expressed recombinant protein can be purified using a glutathione column or nickel column. Alternatively, when the MLX polypeptide is expressed as a protein tagged with c-myc, multiple histidines, or FLAG, it can be detected and purified using antibodies to c-myc, His, or FLAG, respectively.

After purifying the fusion protein, it is also possible to exclude regions other than the objective polypeptide by cutting with thrombin or factor-Xa as required.

A natural protein can be isolated by methods known to a person skilled in the art, for example, by contacting the affinity column, in which antibodies binding to the MLX protein described below are bound, with the extract of tissues or cells expressing the MLX polypeptide. The antibodies can be polyclonal antibodies or monoclonal antibodies.

The MLX polypeptide to be contacted with a test compound can be, for example, a purified polypeptide, a soluble protein, a form bound to a carrier, or a fusion protein fused with other polypeptides. Examples of supports that may be used for binding proteins include insoluble polysaccharides, such as agarose, cellulose, and dextran; and synthetic resins, such as polyacrylamide, polystyrene, and silicon; preferably commercial available beads and plates (e.g., multi-well plates, biosensor chip, etc.) prepared from the above materials may be used. When using beads, they may be filled into a column.

The binding of a protein to a support may be conducted according to routine methods, such as chemical bonding, and physical adsorption. Alternatively, a protein may be bound to a support via antibodies that specifically recognizing the protein. Moreover, binding of a protein to a support can be also conducted by means of avidin and biotin binding.

As a method of screening for proteins, for example, that bind to the MLX polypeptide using any of the MLX polypeptides described above, many methods well known by a person skilled in the art can be used. Such a screening can be conducted by, for example, immunoprecipitation method, specifically, in the following manner.

5 In immunoprecipitation, an immune complex is formed by adding an antibody to cell lysate prepared using an appropriate detergent. The antibody used in the immunoprecipitation for the screening recognizes any of the MLX proteins 1-153. Alternatively, when an MLX protein fused with a recognition site (epitope) is used in the screening, antibodies against the epitope may be used for the immunoprecipitation. The
10 immune complex consists of the MLX protein, a polypeptide comprising the binding ability with the MLX protein, and an antibody.

An immune complex can be precipitated, for example by Protein A sepharose or Protein G sepharose when the antibody is a mouse IgG antibody. If the MLX polypeptide is prepared as a fusion protein with an epitope, such as GST, an immune complex can be
15 formed in the same manner as in the use of the antibody against the MLX polypeptide, using a substance specifically binding to these epitopes, such as glutathione-Sepharose 4B.

Immunoprecipitation can be performed by following or according to, for example, the methods in the literature (Harlow and Lane, Antibodies, 511-52, Cold Spring Harbor Laboratory publications, New York (1988)).

20 SDS-PAGE is commonly used for analysis of immunoprecipitated proteins and the bound protein can be analyzed by the molecular weight of the protein using gels with an appropriate concentration. Since the protein bound to the MLX polypeptide is difficult to detect by a common staining method, such as Coomassie staining or silver staining, the detection sensitivity for the protein can be improved by culturing cells in culture medium
25 containing radioactive isotope, ³⁵S-methionine or ³⁵S-cystein, labeling proteins in the cells, and detecting the proteins. The target protein can be purified directly from the SDS-polyacrylamide gel and its sequence can be determined, when the molecular weight of a protein has been revealed.

As a method for screening proteins binding to the MLX polypeptide using the
30 polypeptide, for example, West-Western blotting analysis (Skolnik et al., Cell 65: 83-90 (1991)) can be used. Specifically, a protein binding to the MLX polypeptide can be obtained by preparing a cDNA library from cells, tissues, organs, or cultured cells expected to express a protein binding to the MLX polypeptide using a phage vector (e.g., ZAP), expressing the protein on LB-agarose, fixing the protein expressed on a filter, reacting the
35 purified and labeled MLX polypeptide with the above filter, and detecting the plaques expressing proteins bound to the MLX polypeptide according to the label. The MLX

polypeptide may be labeled by utilizing the binding between biotin and avidin, or by utilizing an antibody that specifically binds to the MLX polypeptide, or a peptide or polypeptide (for example, GST) that is fused to the MLX polypeptide. Methods using labeling substances such as radioisotope (e.g., ^3H , ^{14}C , ^{32}P , ^{33}P , ^{35}S , ^{125}I , ^{131}I), enzymes (e.g.,
5 alkaline phosphatase, horseradish peroxidase, β -galactosidase, β -glucosidase), fluorescent substances (e.g., fluorescein isothiosyanate (FITC), rhodamine), and biotin/avidin, may be used for the labeling in the present method. When the MLX protein is labeled with radioisotope, the detection or measurement can be carried out by liquid scintillation. Alternatively, MLX proteins labeled with enzymes can be detected or measured by adding
10 a substrate of the enzyme to detect the enzymatic change of the substrate, such as generation of color, with absorptiometer. Further, in case where a fluorescent substance is used as the label, the bound protein may be detected or measured using fluorophotometer.

Alternatively, in another embodiment of the screening method of the present invention, a two-hybrid system utilizing cells may be used ("MATCHMAKER
15 Two-Hybrid system", "Mammalian MATCHMAKER Two-Hybrid Assay Kit", "MATCHMAKER one-Hybrid system" (Clontech); "HybriZAP Two-Hybrid Vector System" (Stratagene); the references "Dalton and Treisman, Cell 68: 597-612 (1992)", "Fields and Sternglanz, Trends Genet 10: 286-92 (1994)").

In the two-hybrid system, the MLX polypeptide is fused to the SRF-binding region
20 or GAL4-binding region and expressed in yeast cells. A cDNA library is prepared from cells expected to express a protein binding to the MLX polypeptide, such that the library, when expressed, is fused to the VP16 or GAL4 transcriptional activation region. The cDNA library is then introduced into the above yeast cells and the cDNA derived from the library is isolated from the positive clones detected (when a protein binding to the MLX
25 polypeptide is expressed in yeast cells, the binding of the two activates a reporter gene, making positive clones detectable). A protein encoded by the cDNA can be prepared by introducing the cDNA isolated above to *E. coli* and expressing the protein.

As a reporter gene, for example, Ade2 gene, lacZ gene, CAT gene, luciferase gene and such can be used besides HIS3 gene.

30 A compound binding to the MLX polypeptide can also be screened using affinity chromatography. For example, the MLX polypeptide may be immobilized on a carrier of an affinity column, and a test compound, containing a protein capable of binding to the MLX polypeptide, is applied to the column. A test compound herein may be, for example, cell extracts, cell lysates, etc. After loading the test compound, the column is washed,
35 and compounds bound to the MLX polypeptide can be prepared.

When the test compound is a protein, the amino acid sequence of the obtained

protein is analyzed, an oligo DNA is synthesized based on the sequence, and cDNA libraries are screened using the oligo DNA as a probe to obtain a DNA encoding the protein.

5 A biosensor using the surface plasmon resonance phenomenon may be used as a mean for detecting or quantifying the bound compound in the present invention. When such a biosensor is used, the interaction between the MLX polypeptide and a test compound can be observed real-time as a surface plasmon resonance signal, using only a minute amount of polypeptide and without labeling (for example, BIAcore, Pharmacia). Therefore, it is possible to evaluate the binding between the MLX polypeptide and a test
10 compound using a biosensor such as BIAcore.

The methods of screening for molecules that bind when the immobilized MLX polypeptide is exposed to synthetic chemical compounds, or natural substance banks, or a random phage peptide display library, or the methods of screening using high-throughput based on combinatorial chemistry techniques (Wrighton et al., Science 273: 458-64 (1996);
15 Verdine, Nature 384: 11-13 (1996); Hogan, Nature 384: 17-9 (1996)) to isolate not only proteins but chemical compounds that bind to the MLX protein (including agonist and antagonist) are well known to one skilled in the art.

A compound isolated by the screening is a candidate for drugs which promote or inhibit the activity of the MLX polypeptide, for treating metastatic lesion of colorectal
20 cancer or preventing metastasis of colorectal cancer. A compound in which a part of the structure of the compound obtained by the present screening method having the activity of binding to the MLX polypeptide is converted by addition, deletion and/or replacement, is included in the compounds obtained by the screening method of the present invention.

Alternatively, when the biological activity of the MLX polypeptide is detected in
25 the screening of the present invention, a compound isolated by this screening is a candidate for agonists or antagonists of the MLX polypeptide. The term "agonist" refers to molecules that activate the function of the MLX polypeptide by binding thereto. Likewise, the term "antagonist" refers to molecules that inhibit the function of the MLX polypeptide by binding thereto. Moreover, a compound isolated by this screening is a
30 candidate for compounds which inhibit the *in vivo* interaction of the MLX polypeptide with molecules (including DNAs and proteins).

When the biological activity to be detected in the present method is cell proliferation, it can be detected, for example, by preparing cells which express the MLX polypeptide, culturing the cells in the presence of a test compound, and determining the
35 speed of cell proliferation, measuring the cell cycle and such, as well as by measuring the colony forming activity.

The compound isolated by the above screenings is a candidate for drugs which inhibit the activity of the MLX polypeptide and can be applied for the treatment of metastatic lesions of colorectal cancer and the prevention of metastasis of colorectal cancer. Moreover, compound in which a part of the structure of the compound inhibiting the activity of the MLX protein is converted by addition, deletion and/or replacement are also included in the compounds obtainable by the screening method of the present invention.

In a further embodiment, the present invention provides methods for screening candidate agents which are potential targets in the treatment of metastatic lesions of colorectal cancer and prevention of metastasis of colorectal cancer. The method is based on screening a candidate therapeutic agent to determine if it converts an expression profile of MLX 1-153 sequences characteristic of metastatic lesions of colorectal cancer to a pattern indicative of a primary lesion of colorectal cancer. As discussed in detail above, by controlling the expression levels of the MLX 1-153, one can control the growth or proliferation of metastatic lesion of colorectal cancer and metastasis of colorectal cancer. Thus, candidate agents, which are potential targets in the treatment of metastatic lesions of colorectal cancer or prevention of metastasis of colorectal cancer, can be identified through screenings that use the expression levels and activities of the MLX polypeptide as indices. In the context of the present invention, such screening may comprise, for example, the following steps: (a) contacting a test compound with a cell expressing one or more marker genes; and (b) selecting a compound that reduces the expression level of the marker gene in comparison with the expression level detected in the absence of the test compound.

Cells expressing at least one of the marker genes include, for example, cell lines established from colorectal cancer, preferably cells from metastatic lesions of colorectal cancer. For example, the cell is an immortalized cell line derived from a metastatic lesion of colorectal cancer. The marker genes for the screening are selected from the group of genes encoding MLXs 1-153.

The expression level can be estimated by methods well known to one skilled in the art. In the method of screening, a compound that reduces the expression level of at least one of the MLX genes can be selected as candidate agents. A decrease in expression compared to the normal control level indicates the agent is an inhibitor of the growth or proliferation of metastatic lesions of colorectal cancer associated up-regulated gene and useful to inhibit development of metastatic lesions of colorectal cancer. An agent effective in suppressing expression of overexpressed genes is deemed to lead to a clinical benefit, and such compounds may be further tested for the ability to inhibit metastasis, cancer cell growth or cancer cell proliferation.

Furthermore, based on this screening method, using a test cell population from a subject as the cell expressing one or more marker genes, therapeutic agents for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer that is appropriate for the subject, *i.e.*, a particular individual can be selected.

5 Differences in the genetic makeup of individuals can result in differences in their relative abilities to metabolize various drugs. An agent that is metabolized in a subject to act as an anti-colorectal cancer agent can manifest itself by inducing a change in gene expression pattern in the subject's cells from that characteristic of a metastatic state to a gene expression pattern characteristic of a non-metastatic state. Accordingly, the
10 differentially expressed MLX sequences disclosed herein allow for a putative therapeutic or prophylactic anti-colorectal cancer agent to be tested in a test cell population from a selected subject in order to determine if the agent is a suitable anti-colorectal cancer agent in the subject.

To identify an anti-colorectal cancer agent, that is appropriate for a specific subject,
15 a test cell population from the subject is exposed to a test compound, and the expression of one or more of MLX 1-153 sequences is determined.

The test cell population contains metastatic lesions of colorectal cancer cells expressing metastasis-associated gene. Preferably, the test cell is an epithelial cell. For example a test cell population is incubated in the presence of a test compound and the
20 pattern of gene expression of one or more of MLX 1-153 sequences in the test cell population is measured and compared to one or more reference profiles, *e.g.*, reference expression profile of primary colorectal cancer with metastasis or non-metastatic colorectal cancer reference expression profile. A decrease in expression of one or more of the sequences MLX 1-153 in a test cell population relative to a reference cell population
25 containing metastatic lesions of colorectal cancer is indicative that the agent is therapeutic.

Further, in another embodiment of the method of screening for a compound for treating colorectal cancer or preventing metastasis of colorectal cancer, the method utilizes the promoter region of an MLX gene. Compounds inhibiting the expression of the MLX
30 gene in colorectal cancer cells are expected to serve as candidates for drugs that can be applied to the treatment of diseases associated with the MLX polypeptide, for example, colorectal carcinoma. Preferably, such compounds are used to treat metastatic lesions of colorectal cancer and to prevent metastasis of colorectal cancer.

This screening method includes the steps of: (1) constructing a vector comprising
35 the transcriptional regulatory region of a gene selected from the group consisting of MLXs 1-153 upstream of a reporter gene; (2) transforming a cell with the vector of step (1); (3)

contacting a test compound with the cell of step (2); (4) detecting the expression of the reporter gene; and (5) selecting the test compound that suppresses the expression of the reporter gene compared to that in the absence of the test compound.

The transcriptional regulatory region of an MLX gene can be obtained from
5 genomic libraries using the 5' region of the human MLX genes (MLX 1-153; see Table 1) as the probe. Any reporter gene may be used in the screening so long as its expression can be detected in the screening. Example of reporter genes include the β -gal gene, the CAT gene, and the luciferase gene. Detection of the expression of the reporter gene can be conducted corresponding to the type of the reporter gene. Although there are no
10 particular restriction on the cell into which the vector is introduced, preferable examples include cells derived from primary lesions of colorectal cancer with metastasis.

The compound isolated by the screening is a candidate for drugs which inhibit the expression of an MLX protein and can be applied to the treatment of colorectal cancer or prevention of metastasis of colorectal cancer. Moreover, compounds in which a part of
15 the structure of the compound inhibiting the transcriptional activation of the MLX protein is converted by addition, deletion, substitution and/ or insertion are also included in the compounds obtainable by the screening method of the present invention.

Any test compound, for example, cell extracts, cell culture supernatant, products of
20 fermenting microorganism, extracts from marine organism, plant extracts, purified or crude proteins, peptides, non-peptide compounds, synthetic micromolecular compounds and natural compounds, can be used in the screening methods of the present invention. The test compound of the present invention can be also obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological
25 libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds
30 (Lam, Anticancer Drug Des 12: 145 (1997)). Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al., Proc Natl Acad Sci USA 90: 6909 (1993); Erb et al., Proc Natl Acad Sci USA 91: 11422 (1994); Zuckermann et al., J Med Chem 37: 2678 (1994); Cho et al., Science 261: 1303 (1993); Carrell et al., Angew Chem Int Ed Engl 33: 2059 (1994); Carell et al., Angew Chem Int Ed
35 Engl 33: 2061 (1994); Gallop et al., J Med Chem 37: 1233 (1994). Libraries of compounds may be presented in solution (e.g., Houghten, Bio Techniques 13: 412 (1992)),

or on beads (Lam, Nature 354: 82 (1991)), chips (Fodor, Nature 364: 555 (1993)), bacteria (U.S. Pat. No. 5,223,409), spores (U.S. Pat. Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al., Proc Natl Acad Sci USA 89: 1865 (1992)) or phage (Scott and Smith, Science 249: 386 (1990); Devlin, Science 249: 404 (1990); Cwirla et al., Proc Natl Acad Sci USA 87: 6378 (1990); Felici, J Mol Biol 222: 301 (1991); United States Patent Application 20020103360).

Kits

The invention also includes an MLX-detection reagent, e.g., a nucleic acid that specifically binds to or identifies one or more MLX nucleic acids such as oligonucleotide sequences, which are complementary to a portion of an MLX nucleic acid. The reagents are packaged together in the form of a kit. The reagents are packaged in separate containers, e.g., a nucleic acid (either bound to a solid matrix or packaged separately with reagents for binding them to the matrix), a control reagent (positive and/or negative), and/or a detectable label. Instructions (e.g., written, tape, VCR, CD-ROM, etc.) for carrying out the assay may be included in the kit. The assay format of the kit is, for example, Northern hybridization.

For example, MLX detection reagent is immobilized on a solid matrix such as a porous strip to form at least one MLX detection site. The measurement or detection region of the porous strip may include a plurality of sites containing a nucleic acid. A test strip may also contain sites for negative and/or positive controls. Alternatively, control sites are located on a separate strip from the test strip. Optionally, the different detection sites may contain different amounts of immobilized nucleic acids, i.e., a higher amount in the first detection site and lesser amounts in subsequent sites. Upon the addition of test sample, the number of sites displaying a detectable signal provides a quantitative indication of the amount of MLX present in the sample. The detection sites may be configured in any suitably detectable shape and are typically in the shape of a bar or dot spanning the width of a teststrip.

Alternatively, the kit contains a nucleic acid substrate array comprising one or more nucleic acid sequences. The nucleic acids on the array specifically identify one or more nucleic acid sequences represented by MLXs 1-153. The expression of 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 40 or 50 or more of the sequences represented by MLX 1-153 is identified by virtue of the level of binding to an array test strip or chip. The substrate array can be on, e.g., a solid substrate, e.g., a "chip" as described in U.S. Patent No. 5,744,305.

Array and pluralities

The invention also includes a nucleic acid substrate array comprising one or more nucleic acid sequences. The nucleic acids on the array specifically corresponds to one or more nucleic acid sequences represented by MLX 1-153. The expression level of 2, 3, 4,
5 5, 6, 7, 8, 9, 10, 15, 20, 25, 40 or 50 or more of the sequences represented by MLX 1-153 are identified by detecting nucleic acid binding to the array.

The invention also includes an isolated plurality (*i.e.*, a mixture if two or more nucleic acids) of nucleic acid sequences. The nucleic acid sequences are in a liquid phase or a solid phase, *e.g.*, immobilized on a solid support such as a nitrocellulose membrane.
10 The plurality includes one or more of the nucleic acid sequences represented by MLX 1-153. In various embodiments, the plurality includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 40 or 50 or more of the sequences represented by MLX 1-153.

Chips

15 The DNA chip is a device that is convenient to compare expression levels of a number of genes at the same time. DNA chip-based expression profiling can be carried out, for example, by the method as disclosed in "Microarray Biochip Technology" (Mark Schena, Eaton Publishing, 2000), etc.

A DNA chip comprises immobilized high-density probes to detect a number of
20 genes. Thus, expression levels of many genes can be estimated at the same time by a single-round analysis. Namely, the expression profile of a specimen can be determined with a DNA chip. The DNA chip-based method of the present invention comprises the following steps of:

- (1) synthesizing aRNAs or cDNAs corresponding to the marker genes;
- 25 (2) hybridizing the aRNAs or cDNAs with probes for marker genes; and
- (3) detecting the aRNA or cDNA hybridizing with the probes and quantifying the amount of mRNA thereof.

The aRNA refers to RNA transcribed from a template cDNA with RNA polymerase. A aRNA transcription kit for DNA chip-based expression profiling is
30 commercially available. With such a kit, aRNA can be synthesized from T7 promoter-attached cDNA as a template using T7 RNA polymerase. On the other hand, by PCR using random primer, cDNA can be amplified using as a template a cDNA synthesized from mRNA.

On the other hand, the DNA chip comprises probes, which have been spotted
35 thereon, to detect the marker genes of the present invention. There is no limitation on the number of marker genes spotted on the DNA chip. For example, it is allowed to select

5% or more, preferably 20% or more, more preferably 50% or more, still more preferably 70 % or more of the marker genes of the present invention. Any other genes as well as the marker genes can be spotted on the DNA chip. For example, a probe for a gene whose expression level is hardly altered may be spotted on the DNA chip. Such a gene
5 can be used to normalize assay results when assay results are intended to be compared between multiple chips or between different assays.

A probe is designed for each marker gene selected, and spotted on a DNA chip. Such a probe may be, for example, an oligonucleotide comprising 5-50 nucleotide residues. A method for synthesizing such oligonucleotides on a DNA chip is known to those skilled
10 in the art. Longer DNAs can be synthesized by PCR or chemically. A method for spotting long DNA, which is synthesized by PCR or the like, onto a glass slide is also known to those skilled in the art. A DNA chip that is obtained by the method as described above can be used for diagnosing metastasis of colorectal cancer.

The prepared DNA chip is contacted with aRNA, followed by the detection of
15 hybridization between the probe and aRNA. The aRNA can be previously labeled with a fluorescent dye. A fluorescent dye such as Cy3(red) and Cy5 (green) can be used to label a aRNA. aRNAs from a subject and a control are labeled with different fluorescent dyes, respectively. The difference in the expression level between the two can be estimated based on a difference in the signal intensity. The signal of fluorescent dye on the DNA
20 chip can be detected by a scanner and analyzed using a special program. For example, the Suite from Affymetrix is a software package for DNA chip analysis.

Methods for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer

25 The invention provides a method for alleviating a symptom of metastasis of colorectal cancer, inhibiting development of metastasis, i.e., growth or proliferation of metastatic lesions of colorectal cancer, or inhibiting metastasis of colorectal cancer in a subject. Therapeutic compounds are administered prophylactically or therapeutically to subject suffering from or at risk of (or susceptible to) developing metastatic lesions of
30 colorectal cancer. Such subjects are identified using standard clinical methods or by detecting an aberrant level of expression or activity of a metastasis-associated gene, e.g., MLX 1-153. Prophylactic administration occurs prior to the manifestation of overt clinical symptoms of disease, such that a disease or disorder is prevented or, alternatively, delayed in its progression.

35 The method includes decreasing the expression, or function, or both, of one or more gene products of genes whose expression is aberrantly increased ("overexpressed gene").

The expression is inhibited in any of several ways known in the art. For example, the expression is inhibited by administering to the subject a compound screened by the screening method of the present invention.

Alternatively, the expression may be inhibited by administering to the subject a
5 nucleic acid that inhibits, or antagonizes, the expression of the overexpressed gene or genes, *e.g.*, an antisense oligonucleotide or small interference RNA (siRNA) which disrupts expression of the overexpressed gene or genes.

Such nucleic acids include polynucleotides which specifically hybridize with the polynucleotide encoding human MLX or the complementary strand thereof, and which
10 comprises at least 15 nucleotides. The term "specifically hybridize" as used herein, means that cross-hybridization does not occur significantly with DNA encoding other proteins, under the usual hybridizing conditions, preferably under stringent hybridizing conditions.

Preferable nucleic acids that inhibit one or more gene products of overexpressed
15 genes include an antisense oligonucleotide that hybridizes with any site within the nucleotide sequence encoding an MLX protein. This antisense oligonucleotide is preferably against at least 15 continuous nucleotides of the nucleotide sequence encoding an MLX protein. The above-mentioned antisense oligonucleotide, which contains an initiation codon in the above-mentioned at least 15 continuous nucleotides, is even more
20 preferred.

Derivatives or modified products of antisense oligonucleotides can be used as antisense oligonucleotides. Examples of such modified products include lower alkyl phosphonate modifications such as methyl-phosphonate-type or ethyl-phosphonate-type, phosphorothioate modifications and phosphoroamidate modifications.

25 The term "antisense oligonucleotides" as used herein means, not only those in which the nucleotides corresponding to those constituting a specified region of a DNA or mRNA are entirely complementary, but also those having a mismatch of one or more nucleotides, as long as the DNA or mRNA and the antisense oligonucleotide can specifically hybridize with the nucleotide sequence encoding an MLX protein.

30 Polynucleotides are contained as those having, in the "at least 15 continuous nucleotide sequence region", when they have a homology of at least 70% or higher, preferably at 80% or higher, more preferably 90% or higher, even more preferably 95% or higher. The algorithm stated herein can be used to determine the homology.

The antisense oligonucleotide derivatives act upon cells producing the MLX
35 polypeptide by binding to the DNA or mRNA encoding the MLX polypeptide, inhibiting its transcription or translation, promoting the degradation of the mRNA, and inhibiting the

expression of the MLX polypeptide, thereby resulting in the inhibition of the MLX polypeptide's function.

The nucleic acids that inhibit one or more gene products of overexpressed genes also include small interfering RNAs (siRNA) comprising a combination of a sense strand
5 nucleic acid and an antisense strand nucleic acid of the nucleotide sequence encoding an MLX protein.

The term "siRNA" refers to a double stranded RNA molecule which prevents translation of a target mRNA. Standard techniques are used for introducing siRNA into cells, including those wherein DNA is used as the template to transcribe RNA. The
10 siRNA comprises a sense nucleic acid sequence and an anti-sense nucleic acid sequence of the polynucleotide encoding a human MLX protein. The siRNA is constructed such that a single transcript (double stranded RNA) has both the sense and complementary antisense sequences from the target gene, *e.g.*, a hairpin.

The method is used to suppress gene expression of a cell with up-regulated
15 expression of an MLX gene. Binding of the siRNA to the MLX gene transcript in the target cell results in a reduction of MLX protein production by the cell. The length of the oligonucleotide is at least 10 nucleotides and may be as long as the naturally occurring transcript. Preferably, the oligonucleotide is 19-25 nucleotides in length. Most preferably, the oligonucleotide is less than 75, 50 or 25 nucleotides in length.

20 The nucleotide sequence of siRNAs may be designed using an siRNA design computer program available from the Ambion website (http://www.ambion.com/techlib/misc/siRNA_finder.html). Nucleotide sequences for the siRNA are selected by the computer program based on the following protocol:

Selection of siRNA Target Sites:

- 25 1. Beginning with the AUG start codon of transcript, scan downstream for AA dinucleotide sequences. Record the occurrence of each AA and the 3' adjacent 19 nucleotides as potential siRNA target sites. Tuschl, et al. recommend not to design siRNA against the 5' and 3' untranslated regions (UTRs) and regions near the start codon (within 75 bases) as these may be richer in regulatory protein binding sites, and
30 thus the complex of endonuclease and siRNAs that were designed against these regions may interfere with the binding of UTR-binding proteins and/or translation initiation complexes.
- 35 2. Compare the potential target sites to the human genome database and eliminate from consideration any target sequences with significant homology to other coding sequences. The homology search can be performed using BLAST, which can be found on the NCBI server at: www.ncbi.nlm.nih.gov/BLAST/

3. Select qualifying target sequences for synthesis. On the website of Ambion, several preferable target sequences can be selected along the length of the gene for evaluation.

5 Alternatively, function of one or more gene products of the overexpressed genes is inhibited by administering a compound that binds to or otherwise inhibits the function of the gene products. For example, the compound is an antibody which binds to the overexpressed gene product or gene products.

10 An antibody that binds to the MLX polypeptide may be in any form, such as monoclonal or polyclonal antibodies, and includes antiserum obtained by immunizing an animal such as a rabbit with the MLX polypeptide, all classes of polyclonal and monoclonal antibodies, human antibodies, and humanized antibodies produced by genetic recombination.

15 An MLX polypeptide used as an antigen to obtain an antibody may be derived from any animal species, but preferably is derived from a mammal such as a human, mouse, or rat, more preferably from a human. A human-derived polypeptide may be obtained from the nucleotide or amino acid sequences disclosed herein (see, Table 1).

20 According to the present invention, the polypeptide to be used as an immunization antigen may be a complete protein or a partial peptide of the protein. A partial peptide may comprise, for example, the amino (N)-terminal or carboxy (C)-terminal fragment of an MLX polypeptide. Herein, an antibody is defined as a protein that reacts with either the full length or a fragment of an MLX polypeptide.

25 A gene encoding an MLX polypeptide or its fragment may be inserted into a known expression vector, which is then used to transform a host cell as described herein. The desired polypeptide or its fragment may be recovered from the outside or inside of host cells by any standard method, and may subsequently be used as an antigen. Alternatively, whole cells expressing the polypeptide or their lysates, or a chemically synthesized polypeptide may be used as the antigen.

30 Any mammalian animal may be immunized with the antigen, but preferably the compatibility with parental cells used for cell fusion is taken into account. In general, animals of Rodentia, Lagomorpha or Primates are used. Animals of Rodentia include, for example, mouse, rat and hamster. Animals of Lagomorpha include, for example, rabbit. Animals of Primates include, for example, a monkey of Catarrhini (old world monkey) such as *Macaca fascicularis*, rhesus monkey, sacred baboon and chimpanzees.

35 Methods for immunizing animals with antigens are known in the art. Intraperitoneal injection or subcutaneous injection of antigens is a standard method for

immunization of mammals. More specifically, antigens may be diluted and suspended in an appropriate amount of phosphate buffered saline (PBS), physiological saline, etc. If desired, the antigen suspension may be mixed with an appropriate amount of a standard adjuvant, such as Freund's complete adjuvant, made into emulsion, and then administered to mammalian animals. Preferably, it is followed by several administrations of antigen mixed with an appropriately amount of Freund's incomplete adjuvant every 4 to 21 days. An appropriate carrier may also be used for immunization. After immunization as above, serum is examined by a standard method for an increase in the amount of desired antibodies.

Polyclonal antibodies against the MLX polypeptides may be prepared by collecting blood from the immunized mammal examined for the increase of desired antibodies in the serum, and by separating serum from the blood by any conventional method. Polyclonal antibodies include serum containing the polyclonal antibodies, as well as the fraction containing the polyclonal antibodies may be isolated from the serum. Immunoglobulin G or M can be prepared from a fraction which recognizes only the MLX polypeptide using, for example, an affinity column coupled with the MLX polypeptide, and further purifying this fraction using protein A or protein G column.

To prepare monoclonal antibodies, immune cells are collected from the mammal immunized with the antigen and checked for the increased level of desired antibodies in the serum as described above, and are subjected to cell fusion. The immune cells used for cell fusion are preferably obtained from spleen. Other preferred parental cells to be fused with the above immunocyte include, for example, myeloma cells of mammals, and more preferably myeloma cells having an acquired property for the selection of fused cells by drugs.

The above immunocyte and myeloma cells can be fused according to known methods, for example, the method of Milstein et al. (Galfre and Milstein, *Methods Enzymol* 73: 3-46 (1981)).

Resulting hybridomas obtained by the cell fusion may be selected by cultivating them in a standard selection medium, such as HAT medium (hypoxanthine, aminopterin, and thymidine containing medium). The cell culture is typically continued in the HAT medium for several days to several weeks, the time being sufficient to allow all the other cells, with the exception of the desired hybridoma (non-fused cells), to die. Then, the standard limiting dilution is performed to screen and clone a hybridoma cell producing the desired antibody.

In addition to the above method, in which a non-human animal is immunized with an antigen for preparing hybridoma, human lymphocytes such as those infected by EB

virus may be immunized with a polypeptide, polypeptide expressing cells, or their lysates *in vitro*. Then, the immunized lymphocytes are fused with human-derived myeloma cells that are capable of indefinitely dividing, such as U266, to yield a hybridoma producing a desired human antibody that is able to bind to the MLX polypeptide can be obtained

5 (Unexamined Published Japanese Patent Application No. (JP-A) Sho 63-17688).

The obtained hybridomas are subsequently transplanted into the abdominal cavity of a mouse and the ascites are extracted. The obtained monoclonal antibodies can be purified by, for example, ammonium sulfate precipitation, a protein A or protein G column, DEAE ion exchange chromatography, or an affinity column to which the MLX polypeptide
10 is coupled. The antibody serve as a candidate for agonists and antagonists of the MLX polypeptide and can be applied to the antibody treatment for diseases related to the MLX polypeptide. When the obtained antibody is to be administered to the human body (antibody treatment), a human antibody or a humanized antibody is preferable for reducing immunogenicity.

15 For example, transgenic animals having a repertory of human antibody genes may be immunized with an antigen selected from a polypeptide, polypeptide expressing cells, or their lysates. Antibody producing cells are then collected from the animals and fused with myeloma cells to obtain hybridoma, from which human antibodies against the polypeptide can be prepared (see WO92-03918, WO93-2227, WO94-02602, WO94-25585,
20 WO96-33735, and WO96-34096).

Alternatively, an immune cell, such as an immunized lymphocyte, producing antibodies may be immortalized by an oncogene and used for preparing monoclonal antibodies.

Monoclonal antibodies thus obtained can be also recombinantly prepared using
25 genetic engineering techniques (see, for example, Borrebaeck and Larrick, Therapeutic Monoclonal Antibodies, published in the United Kingdom by MacMillan Publishers LTD (1990)). For example, a DNA encoding an antibody may be cloned from an immune cell, such as a hybridoma or an immunized lymphocyte producing the antibody, inserted into an appropriate vector, and introduced into host cells to prepare a recombinant antibody.

30 Furthermore, an antibody used for the method of treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer of the present invention may be a fragment of an antibody or modified antibody, so long as it binds to one or more of the MLX polypeptides. For instance, the antibody fragment may be Fab, F(ab')₂, Fv, or single chain Fv (scFv), in which Fv fragments from H and L chains are ligated by an
35 appropriate linker (Huston et al., Proc Natl Acad Sci USA 85: 5879-83 (1988)). More specifically, an antibody fragment may be generated by treating an antibody with an

enzyme, such as papain or pepsin. Alternatively, a gene encoding the antibody fragment may be constructed, inserted into an expression vector, and expressed in an appropriate host cell (see, for example, Co et al., *J Immunol* 152: 2968-76 (1994); Better and Horwitz, *Methods Enzymol* 178: 476-96 (1989); Pluckthun and Skerra, *Methods Enzymol* 178: 497-515 (1989); Lamoyi, *Methods Enzymol* 121: 652-63 (1986); Rousseaux et al., *Methods Enzymol* 121: 663-9 (1986); Bird and Walker, *Trends Biotechnol* 9: 132-7 (1991)).

An antibody may be modified by conjugation with a variety of molecules, such as polyethylene glycol (PEG). The modified antibody can be obtained by chemically modifying an antibody. These modification methods are conventional in the field.

Alternatively, an antibody may be obtained as a chimeric antibody, between a variable region derived from nonhuman antibody and the constant region derived from human antibody, or as a humanized antibody, comprising the complementarity determining region (CDR) derived from nonhuman antibody, the frame work region (FR) derived from human antibody, and the constant region. Such antibodies can be prepared using known technology.

Antibodies obtained as above may be purified to homogeneity. For example, the separation and purification of the antibody can be performed according to separation and purification methods used for general proteins. For example, the antibody may be separated and isolated by the appropriately selected and combined use of column chromatographies, such as affinity chromatography, filter, ultrafiltration, salting-out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing, and others (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988)), but are not limited thereto. A protein A column and protein G column can be used as the affinity column. Exemplary protein A columns to be used include, for example, Hyper D, POROS, and Sepharose F.F. (Pharmacia).

Exemplary chromatography, with the exception of affinity includes, for example, ion-exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, adsorption chromatography, and the like (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press (1996)). The chromatographic procedures can be carried out by liquid-phase chromatography, such as HPLC, FPLC.

For example, measurement of absorbance, enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), radioimmunoassay (RIA), and/or immunofluorescence may be used to measure the antigen binding activity of the antibody against an MLX protein. In ELISA, the antibody is immobilized on a plate, an MLX

polypeptide is applied to the plate, and then a sample containing a desired antibody, such as culture supernatant of antibody producing cells or purified antibodies, is applied. Then, a secondary antibody that recognizes the primary antibody and is labeled with an enzyme, such as alkaline phosphatase, is applied, and the plate is incubated. Next, after washing, an enzyme substrate, such as *p*-nitrophenyl phosphate, is added to the plate, and the absorbance is measured to evaluate the antigen binding activity of the sample. A fragment of the polypeptide, such as a C-terminal or N-terminal fragment, may be used as the antigen to evaluate the binding activity of the antibody. BIAcore (Pharmacia) may be used to evaluate the activity of the antibody against an MLX protein.

The present invention provides a method for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer, using an antibody against an MLX polypeptide. According to the method, a pharmaceutically effective amount of an antibody against the MLX polypeptide is administered. Since the expression of the MLX protein is up-regulated in metastatic lesions of colorectal cancer, and the suppression of the expression of these proteins is expected to lead to suppression of the growth or proliferation of the metastatic lesion, it is expected that metastatic lesion of colorectal cancer can be treated or prevented, or metastasis of colorectal cancer can be suppressed or prevented by binding the antibody and these proteins. Thus, an antibody against an MLX polypeptide are administered at a dosage sufficient to reduce the activity of the MLX protein. Alternatively, an antibody binding to a cell surface marker specific for tumor cells can be used as a tool for drug delivery. Thus, for example, an antibody against an MLX polypeptide conjugated with a cytotoxic agent may be administered at a dosage sufficient to injure tumor cells.

Furthermore, the present invention provides a method for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer by administering an MLX polypeptide, a polynucleotide encoding the polypeptide or a vector comprising the polynucleotide. The MLX proteins and immunologically active fragments thereof are useful as vaccines against metastatic lesions of colorectal cancer or metastasis of colorectal cancer. Thus, the present invention also relates to a method of inducing anti-tumor immunity comprising the step of administering an MLX protein or an immunologically active fragment thereof, a polynucleotide encoding the protein or fragments thereof, or a vector comprising the polynucleotide. In some cases the proteins or fragments thereof may be administered in a form bound to the T cell receptor (TCR) or presented by an antigen presenting cell (APC), such as macrophage, dendritic cell (DC) or B-cells. Due to the strong antigen presenting ability of DC, the use of DC is most preferable among the

APCs.

In the present invention, vaccine against metastatic lesion of colorectal cancer or metastasis of colorectal cancer refers to a substance that has the function to induce anti-tumor immunity or immunity to suppress metastasis or growth or proliferation of metastatic lesion upon inoculation into animals. In general, anti-tumor immunity includes immune responses such as follows:

- induction of cytotoxic lymphocytes against tumors,
- induction of antibodies that recognize tumors, and
- induction of anti-tumor cytokine production.

Therefore, when a certain protein induces any one of these immune responses upon inoculation into an animal, the protein is decided to have anti-tumor immunity inducing effect. The induction of the anti-tumor immunity by a protein can be detected by observing *in vivo* or *in vitro* the response of the immune system in the host against the protein.

For example, a method for detecting the induction of cytotoxic T lymphocytes is well known. A foreign substance that enters the living body is presented to T cells and B cells by the action of antigen presenting cells (APCs). T cells that respond to the antigen presented by APC in antigen specific manner differentiate into cytotoxic T cells (or cytotoxic T lymphocytes; CTLs) due to stimulation by the antigen, and then proliferate (this is referred to as activation of T cells). Therefore, CTL induction by a certain peptide can be evaluated by presenting the peptide to T cell by APC, and detecting the induction of CTL. Furthermore, APC has the effect of activating CD4+ T cells, CD8+ cells, macrophages, eosinophils, and NK cells. Since CD4+ T cells and CD8+ cells are also important in anti-tumor immunity, the anti-tumor immunity inducing action of the peptide can be evaluated using the activation effect of these cells as indicators.

A method for evaluating the inducing action of CTL using dendritic cells (DCs) as APC is well known in the art. DC is a representative APC having the strongest CTL inducing action among APCs. In this method, the test polypeptide is initially contacted with DC, and then this DC is contacted with T cells. Detection of T cells having cytotoxic effects against the cells of interest after the contact with DC shows that the test polypeptide has an activity of inducing the cytotoxic T cells. Activity of CTL against tumors can be detected, for example, using the lysis of ⁵¹Cr-labeled tumor cells as the indicator. Alternatively, the method of evaluating the degree of tumor cell damage using ³H-thymidine uptake activity or LDH (lactose dehydrogenase)-release as the indicator is also well known.

Apart from DC, peripheral blood mononuclear cells (PBMCs) may also be used as

the APC. The induction of CTL is reported that the it can be enhanced by culturing PBMC in the presence of GM-CSF and IL-4. Similarly, CTL has been shown to be induced by culturing PBMC in the presence of keyhole limpet hemocyanin (KLH) and IL-7.

5 The test polypeptides confirmed to possess CTL inducing activity by these methods are polypeptides having DC activation effect and subsequent CTL inducing activity. Therefore, polypeptides that induce CTL against tumor cells are useful as vaccines against tumors. Furthermore, APC that acquired the ability to induce CTL against tumors by contacting with the polypeptides are useful as vaccines against tumors.
10 Furthermore, CTL that acquired cytotoxicity due to presentation of the polypeptide antigens by APC can be also used as vaccines against tumors. Such therapeutic methods for tumors using anti-tumor immunity due to APC and CTL are referred to as cellular immunotherapy.

 Generally, when using a polypeptide for cellular immunotherapy, efficiency of the
15 CTL-induction is known to increase by combining a plurality of polypeptides having different structures and contacting them with DC. Therefore, when stimulating DC with protein fragments, it is advantageous to use a mixture of multiple types of fragments.

 Alternatively, the induction of anti-tumor immunity by a polypeptide can be confirmed by observing the induction of antibody production against tumors. For
20 example, when antibodies against a polypeptide are induced in a laboratory animal immunized with the polypeptide, and when growth, proliferation or metastasis of tumor cells is suppressed by those antibodies, the polypeptide can be determined to have an ability to induce anti-tumor immunity.

 Anti-tumor immunity is induced by administering the vaccine of this invention,
25 and the induction of anti-tumor immunity enables treatment of metastatic lesion of colorectal cancer and prevention of metastasis of colorectal cancer. Therapy against cancer, or prevention of the onset of cancer or metastasis of cancer includes any of the steps, such as inhibition of the growth of cancerous cells (including primary cancer cells and metastatic lesion cells), involution of cancer, suppression of occurrence of cancer, and
30 metastasis of cancer. Decrease in mortality of individuals having cancer, decrease of tumor markers in the blood, alleviation of detectable symptoms accompanying cancer, and such are also included in the therapy or prevention of cancer. Such therapeutic and preventive effects are preferably statistically significant. For example, in observation, at a significance level of 5% or less, wherein the therapeutic or preventive effect of a vaccine
35 against cell proliferative diseases is compared to a control without vaccine administration. For example, Student's t-test, the Mann-Whitney U-test, or ANOVA may be used for

statistical analyses.

The above-mentioned protein having immunological activity, or a polynucleotide or vector encoding the protein may be combined with an adjuvant. An adjuvant refers to a compound that enhances the immune response against the protein when administered
5 together (or successively) with the protein having immunological activity. Examples of adjuvants include cholera toxin, salmonella toxin, alum, and such, but are not limited thereto. Furthermore, the vaccine of this invention may be combined appropriately with a pharmaceutically acceptable carrier. Examples of such carriers are sterilized water, physiological saline, phosphate buffer, culture fluid, and such. Furthermore, the vaccine
10 may contain as necessary, stabilizers, suspensions, preservatives, surfactants, and such. The vaccine is administered systemically or locally. Vaccine administration may be performed by single administration, or boosted by multiple administrations.

When using APC or CTL as the vaccine of this invention, tumors can be treated or prevented, for example, by the *ex vivo* method. More specifically, PBMCs of the subject
15 receiving treatment or prevention are collected, the cells are contacted with the polypeptide *ex vivo*, and following the induction of APC or CTL, the cells may be administered to the subject. APC can be also induced by introducing a vector encoding the polypeptide into PBMCs *ex vivo*. APC or CTL induced in vitro can be cloned prior to administration. By cloning and growing cells having high activity of damaging target cells, cellular
20 immunotherapy can be performed more effectively. Furthermore, APC and CTL isolated in this manner may be used for cellular immunotherapy not only against individuals from whom the cells are derived, but also against similar types of tumors from other individuals.

Composition for treating metastatic lesion of colorectal cancer or preventing metastasis of 25 colorectal cancer

When administering the compound isolated by the screening methods of the invention as a pharmaceutical for humans and other mammals, such as mice, rats, guinea-pigs, rabbits, chicken, cats, dogs, sheep, pigs, cattle, monkeys, baboons, chimpanzees, for treating metastatic lesion of colorectal cancer or preventing metastasis of
30 colorectal cancer the isolated compound can be directly administered or can be formulated into a dosage form using known pharmaceutical preparation methods.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration, or for administration by inhalation or
35 insufflation. The formulations are optionally packaged in discrete dosage units.

Pharmaceutical formulations suitable for oral administration include capsules,

cachets or tablets, each containing a predetermined amount of the active ingredient. Formulations also include powders, granules or solutions, suspensions or emulsions. The active ingredient is optionally administered as a bolus electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrant or wetting agents. A tablet may be made by compression or molding, optionally with one or more formulation ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be coated according to methods well known in the art. Oral fluid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives. The tablets may optionally be formulated so as to provide slow or controlled release of the active ingredient therein. A package of tablets may contain one tablet to be taken on each of the month.

Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Alternatively, the formulations may be presented for continuous infusion. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Formulations for rectal administration include suppositories with standard carriers such as cocoa butter or polyethylene glycol. Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges, which contain the active ingredient in a flavored base such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a base such as gelatin and glycerin or sucrose and acacia. For intra-nasal administration the compounds of the invention may be used as a

liquid spray or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents.

For administration by inhalation the compounds are conveniently delivered from an insufflator, nebulizer, pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the compounds may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflators.

Other formulations include implantable devices and adhesive patches; which release a therapeutic agent.

When desired, the above-described formulations, adapted to give sustained release of the active ingredient, may be employed. The pharmaceutical compositions may also contain other active ingredients such as antimicrobial agents, immunosuppressants or preservatives.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents, surfactants, stabilizers, excipients, vehicles, preservatives, binders and such, in a unit dose form required for generally accepted drug implementation.

Methods well known to one skilled in the art may be used to administer the inventive pharmaceutical compound to patients, for example as intraarterial, intravenous, percutaneous injections and also as intranasal, transbronchial, intramuscular or oral administrations. The dosage and method of administration vary according to the body-weight and age of a patient and the administration method; however, one skilled in the art can routinely select them. If said compound is encodable by a DNA, the DNA can be inserted into a vector for gene therapy and the vector administered to perform the therapy. The dosage and method of administration vary according to the body-weight, age, and symptoms of a patient but one skilled in the art can select them suitably.

For example, although there are some differences according to the symptoms, the

dose of a compound that binds with the polypeptide of the present invention and regulates its activity is about 0.1 mg to about 100 mg per day, preferably about 1.0 mg to about 50 mg per day and more preferably about 1.0 mg to about 20 mg per day, when administered orally to a normal adult (weight 60 kg).

5 When administering parenterally, in the form of an injection to a normal adult (weight 60 kg), although there are some differences according to the patient, target organ, symptoms and method of administration, it is convenient to intravenously inject a dose of about 0.01 mg to about 30 mg per day, preferably about 0.1 to about 20 mg per day and more preferably about 0.1 to about 10 mg per day. Also, in the case of other animals too,
10 it is possible to administer an amount converted to 60kgs of body-weight.

The present invention provides a composition for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer using an antisense oligonucleotide derivative or siRNA derivative against one or more MLX genes as the
15 active ingredients. The derivatives can be made into an external preparation, such as a liniment or a poultice, by mixing with a suitable base material which is inactive against the derivatives.

Also, as needed, the derivatives can be formulated into tablets, powders, granules, capsules, liposome capsules, injections, solutions, nose-drops and freeze-drying agents by
20 adding excipients, isotonic agents, solubilizers, stabilizers, preservatives, pain-killers, and such. These can be prepared by following usual methods.

The antisense oligonucleotide derivative or siRNA derivative is given to the patient by directly applying onto the ailing site or by injecting into a blood vessel so that it will reach the site of ailment. A mounting medium can also be used to increase durability and
25 membrane-permeability. Examples are, liposome, poly-L-lysine, lipid, cholesterol, lipofectin or derivatives of these.

The dosage of the antisense oligonucleotide derivative or siRNA derivative of the present invention can be adjusted suitably according to the patient's condition and used in desired amounts. For example, a dose range of 0.1 to 100 mg/kg, preferably 0.1 to 50
30 mg/kg can be administered.

The present invention further provides a composition for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer by administering an antibody against an MLX protein or fragment thereof to a subject.

35 Furthermore, a composition for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer, comprising a pharmaceutically effective amount

of an MLX polypeptide is provided. The composition comprising the MLX protein may be used for raising anti tumor immunity. Moreover, in place of an MLX protein, polynucleotides or vectors encoding the MLX protein may be administered to the subject for treating colorectal cancer and preventing metastasis of colorectal cancer. The form of the polynucleotides and vectors encoding the MLX protein is not restricted in any way so long as they express the MLX protein or fragments thereof in the subject and induce anti-tumor immunity in the subject.

For example, although there are some differences according to the symptoms, the dose of an antibody or polypeptide for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer is about 0.1 mg to about 100 mg per day, preferably about 1.0 mg to about 50 mg per day and more preferably about 1.0 mg to about 20 mg per day, when administered orally to a normal adult (weight 60 kg).

When administering parenterally, in the form of an injection to a normal adult (weight 60 kg), although there are some differences according to the patient, target organ, symptoms and method of administration, it is convenient to intravenously inject a dose of about 0.01 mg to about 30 mg per day, preferably about 0.1 to about 20 mg per day and more preferably about 0.1 to about 10 mg per day. Also, in the case of other animals too, it is possible to administer an amount converted to 60kgs of body-weight.

The following examples are presented to illustrate the present invention and to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the invention.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. Any patents, patent applications, and publications cited herein are incorporated by reference.

Best Mode for Carrying out the Invention

The present invention is illustrated in details by following Examples, but is not restricted to these Examples.

1. Materials and Methods

(1) Tissue samples and laser-capture microdissection (LCM)

Primary CRC tissues and corresponding metastatic foci from liver were obtained with informed consent from 15 patients who underwent colectomy and hepatectomy in the

same operation. All of the samples were imbedded in TissueTek OCT medium (Sakura, Tokyo, Japan) and frozen at -80°C . Later, the frozen sections were fixed in 70% ethanol for 45 sec., stained with hematoxylin and eosin, and dehydrated in 70:30, 50:50, and 30:70 of ethanol: xylene for 30 sec. in each step, followed by a final dehydration in 100% xylene for two min. Upon air-drying, the stained tissues were microdissected using PixCell LCM system (Arcturus Engineering, Mountain View, CA) according to the manufacturer's protocols. Cancerous cells from the primary lesions were selectively microdissected ($\sim 2 \times 10^4$ cells from each sample).

(2) RNA extraction and T7-based RNA amplification

Total RNAs were extracted from each sample of the laser-captured cells into 350 μl of RLT lysis buffer (QIAGEN, Hilden, Germany). The extracted RNAs were treated for 1h at 37°C with 10 units of DNase I (Roche, Basel, Switzerland) in the presence of 1U of RNase inhibitor (TOYOBO, Osaka, Japan) to remove any contaminating genomic DNAs. After inactivation at 70°C for 10 min, the RNAs were purified with RNeasy Mini Kit (QIAGEN) according to the manufacturer's recommendations. All DNase I-treated RNAs were subjected to T7-based amplification as described previously (Ono et al., Cancer Res 60: 5007-11 (2000)). Two rounds of amplification yielded 15-80 μg of amplified RNA (aRNA) from each sample.

(3) Construction and analysis of cDNA microarray

23040 independent cDNAs were selected, including some ESTs, from the UniGene database of the National Center for Biotechnology Information. The DNA spotted on the microarray slides were prepared by RT-PCR using sets of gene-specific primers and a mixture of commercially provided poly A RNAs (Clontech, Palo Alto, CA) as a template (Ono et al., Cancer Res 60: 5007-11 (2000)). The products were applied to electrophoresis on agarose gels and those showing a single band of expected size were utilized for spotting. Further sequence analyses of randomly selected 2485 products from 23040 genes collaborated the complete concordance of their cDNA sequences.

Duplicate sets of cDNA spots were used for each analysis of expression profiles, to reduce experimental fluctuation. Three-microgram aliquots of aRNA from each primary tumor and normal epithelium were labeled respectively with Cy3-dCTP and Cy5-dCTP (Amersham Pharmacia Biotech) to compare the expression between primary lesion and non-cancerous mucosa. Equal amounts of Cy3- and Cy5-labeled probes were co-hybridized onto the microarray slides. Hybridization, washing, and scanning were performed as described previously (Ono et al., Cancer Res 60: 5007-11 (2000)).

(4) Data analysis

The intensity of each duplicated signal was evaluated photometrically by the

Array Vision computer program (Imaging Research Inc., St. Catharines, Ontario, Canada) and normalized so that the averaged Cy3/Cy5-ratio of 52 housekeeping genes that had been spotted on the microarray slides was 1.0 (Kitahara et al., Cancer Res 61: 3544-9 (2001); Ono et al., Cancer Res 60: 5007-11 (2000)). Because data derived from low
5 signal intensities are less reliable, cut-off values for signal intensities were determined on each slide so that all filtered genes have greater S/N (signal to noise) ratios of Cy3 or Cy5 than three and excluded genes for further analysis when both Cy3 and Cy5 dyes gave signal intensities lower than the cut-off. The Cy3/Cy5 ratio for each gene was calculated by averaging duplicate spots (Kitahara et al., Cancer Res 61: 3544-9 (2001); Ono et al.,
10 Cancer Res 60: 5007-11 (2000)). For the comparison between primary and metastatic lesions, genes whose Cy3/Cy5 ratios were greater than two were considered to be up-regulated in the metastatic tissues. Finally, genes that showed up-regulated expression in half or more of cases with significant intensities were selected as "frequently up-regulated" genes. In respect to the comparison between non-cancerous mucosae and
15 primary tumors, genes were categorized into three groups according to their expression ratios (Cy3/Cy5): up-regulated (ratio equal to or greater than 2.0), down-regulated (ratio equal to or less than 0.5), and unchanged expression (ratios between 0.5 and 2.0). Genes with Cy3/Cy5 ratios greater than 2.0 or less than 0.5 in more than 50% of the cases examined were defined as frequently up- or down-regulated genes, respectively.

20

2. Results

(1) Isolation of primary CRCs and corresponding metastatic lesions by LCM

To obtain precise expression profiles of primary and metastatic cancer cells, laser-capture microdissection (LCM) was employed to collect pure populations of each
25 type. The proportion of cancer cells selected by this procedure was estimated to be >95%, as determined by microscopic visualization (data not shown). The hepatocyte contamination in the microdissected metastatic lesions was previously estimated to be less than 0.3% (Yamagawa, Neoplasia 3: 395-401 (2001)).

(2) Identification of genes frequently up-regulated in primary CRCs with liver metastasis 30 but not in those without metastasis or premalignant tumors

To identify genes whose expression is involved in liver metastasis, first, genes whose expression levels were altered between primary lesions and metastatic lesions were selected. From the pharmacogenetic point of view, suppressing metastatic signals is easier in practice than activating metastasis-suppressive effects. Therefore, genes whose
35 expression was up-regulated in metastatic lesion were focused in the present invention. The selected genes as judged by their ratios of signal intensity of metastatic to primary

cancer tissues in each case, varied because of the inevitable diversity among individual tumors and the variety of factors that could affect gene expression. Thus, genes whose expression in metastatic tissue was elevated more than two-fold in equal to or more than half of cases with significant signal intensities were selected for further study. The criteria identified 153 frequently up-regulated genes including 37 ESTs (Table 1). These genes may include not only genes related directly metastatic process such as migration, vessel invasion, and/or attachment to vessels in the liver, but also genes associated to the growth of cancerous lesion in the metastasized environment.

Table 1. Frequently Up-regulated Genes in the Metastatic Lesions

MLX Assignment	LMM ID	Symbol	Title	ACCESSIO N	Unigene- ID
1	A0775	CUTL1	cut (Drosophila)-like 1 (CCAAT displacement protein)	L12579	147049
2	A2906	RAB31	RAB31, member RAS oncogene family	U59877	223025
3	A2888	KLK1	kallikrein 1, renal/pancreas/salivary	M25629	123107
4	A4841	SCAM	vinexin beta (SH3-containing adaptor molecule)	AF037261	33787
5	A3990	STK29	serine/threonine kinase 29	AJ006701	170819
6	A4428	CD86	CD86 antigen (CD28 antigen ligand 2, B7-2 antigen)	U04343	27954
7	A2983	ARL1	ADP-ribosylation factor-like 1	L28997	242894
8	A3138	LHX2	LIM homeobox protein 2	U11701	1569
9	A0158	PECAM1	platelet/endothelial cell adhesion molecule (CD31 antigen)	M28526	78146
10	A4390	TGFB1I1	transforming growth factor beta 1 induced transcript 1	AB007836	25511
11	A1527	CD6	CD6 antigen	U34623	81226
12	A0236	CDC27	cell division cycle 27	U00001	297170
13	A6267	PSMD9	proteasome (prosome, macropain) 26S subunit, non-ATPase, 9	AB003177	5648
14	A0348	TYK2	tyrosine kinase 2	X54637	75516
15	A2398	MAP3K11	mitogen-activated protein kinase kinase kinase 11	L32976	89449
16	A5363		DKFZP586J1624 protein	AI027554	4964
17	A3524	PTPNS1	protein tyrosine phosphatase, non-receptor type substrate 1	D86043	156114
18	A5514	ASMTL	acetylserotonin O-methyltransferase-like	AA669799	6315
19	A5533	HTATIP	HIV Tat interactive protein, 60 kDa	U40989	6364
20	A2790	PRM2	protamine 2	X07862	2324
21	A4812	NTE	neuropathy target esterase	AJ004832	5038
22	A4027	HDAC1	histone deacetylase 1	D50405	88556
23	A4300	ZNF198	zinc finger protein 198	Y13472	109526
24	A5984	YF13H12	protein expressed in thyroid	AI246770	7486
25	A5469	ILK	integrin-linked kinase	U40282	6196

26	A1329	DTX1	deltex (Drosophila) homolog 1	AF053700	124024
27	A6404		ESTs	AA292973	7739
28	A4388	EVPL	envoplakin	U53786	25482
29	A2117	PFN1	profilin 1	J03191	75721
30	A5949	TCTA	T-cell leukemia translocation		
31	A3653	CHES1	altered gene	AA148963	250894
32	A2800	GPX4	checkpoint suppressor 1	U68723	211773
33	A6118	C6orf4	glutathione peroxidase 4		
34	A1673	NDRG1	(phospholipid hydroperoxidase)	X71973	2706
35	A6043	KRT19	chromosome 6 open reading frame		
36	D0491	SLC6A8	4	AA678713	7446
37	A5680		N-myc downstream regulated	D87953	75789
38	A6074	DUSP16	keratin 19	H63283	182265
39	B7824		solute carrier family 6		
40	C3979		(neurotransmitter transporter,	AA815427	187958
41	A6056		creatine), member 8		
42	B8316		Homo sapiens mRNA; cDNA	W55926	5288
43	B2484	SORT1	DKFZp434M245 (from clone	AA341957	20281
44	C7756		DKFZp434M245)	AA236315	22283
45	C6135		dual specificity phosphatase 16		
46	A2216	PPM1G	Homo sapiens cDNA: FLJ21175	AA543086	126759
47	A6234	ADH1	fis, clone CAS11071	AA039992	7296
48	A2557	DF	Homo sapiens cDNA: FLJ23270	AI268685	279945
49	A3705	BMPR1B	fis, clone COL10309, highly	AI271791	281706
50	A5309	MP1	similar to HSU33271 Human	H03641	177664
51	A0190	MCC	normal keratinocyte mRNA	AI128203	57988
52	A0875	NR4A1	hypothetical protein FLJ10587		
53	A0831	KRT5	HSPC023 protein	Y13936	17883
54	A7566		sortilin 1	M12963	73843
			KIAA0914 gene product	M84526	155597
			hypothetical protein FLJ22357	U89326	87223
			similar to epidermal growth factor	AI140756	260116
			receptor-related protein	M62397	1345
			protein phosphatase 1G (formerly	L13740	1119
			2C), magnesium-dependent,		
			gamma isoform	M21389	195850
			alcohol dehydrogenase 1 (class I),	W58209	103118
			alpha polypeptide		
			D component of complement		
			(adipsin)		
			bone morphogenetic protein		
			receptor, type IB		
			metalloprotease 1 (pitrilysin family)		
			mutated in colorectal cancers		
			nuclear receptor subfamily 4, group		
			A, member 1		
			keratin 5 (epidermolysis bullosa		
			simplex,		
			Dowling-Meara/Kobner/Weber-Co		
			ckayne types)		
			ESTs		

55	B7703		hypothetical protein FLJ10432	U69190	143187
56	B0544		EST	T92887	115826
57	B1913		KIAA1138 protein	AI312123	115726
58	B0994		hypothetical protein FLJ20500	AA522530	111244
59	D8848		Homo sapiens cDNA FLJ13458 fis, clone PLACE1003361	AA724079	131798
60	A0378	ADM	adrenomedullin serine (or cysteine) proteinase inhibitor, clade A (alpha antiproteinase, antitrypsin), member 1	D14874	394
61	A2074	SERPINA1	hepatocellular carcinoma associated protein; breast cancer associated gene 1	K01396	75621
62	A5355	JCL	Down syndrome critical region gene 3	AA478499	4943
63	A4401	DSCR3	porcupine small nuclear ribonucleoprotein 70kD polypeptide (RNP antigen)	D87343	26146
64	A5700	MG61	inosine triphosphatase	AA305489	5326
65	A1593	SNRP70	lectin, mannose-binding, 1	X04654	174051
66	A6283	ITPA	creatine kinase, brain	AF026816	6817
67	A4718	LMAN1	sigma receptor (SR31747 binding protein 1)	U09716	287912
68	A1030	CKB	ESTs	L47647	173724
69	A4366	SR-BP1		U75283	24447
70	B3732 B5359			AA583350	30701
71	N	DXS1357E	accessory proteins BAP31/BAP29 ESTs, Highly similar to I38945 melanoma ubiquitous mutated protein [H.sapiens] vascular endothelial	U36341	291904
72	C7658		junction-associated molecule	AA143060	71741
73	C4163	VE-JAM	hypothetical protein FLJ11252	AA912674	54650
74	E1428		casein kinase 2, alpha 1 polypeptide tumor necrosis factor receptor superfamily, member 1A	BE614190	23495
75	A2219	CSNK2A1		M55265	155140
76	A0182	TNFRSF1A	dead ringer (Drosophila)-like 1	M58286	159
77	A7124	DRIL1	hypothetical protein LOC57822	U88047	198515
78	D9015		ESTs	AI041354	132127
79	B7655			T74135	13233
80	A5442	KLF4	Kruppel-like factor 4 (gut) ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate)	AI290876	7934
81	A3349	EMS1		M98343	119257
82	A4792	TSPAN-5	tetraspan 5	AF065389	20709
83	A5177	E4F1	E4F transcription factor 1	U87269	154196
84	A2775	VSNL1	visinin-like 1 polymerase (DNA directed), delta 1, catalytic subunit (125kD)	AA774776	2288
85	A3320	POLD1		M80397	99890

86	A1522	SEMA3B	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B	U28369	82222
87	A2976	HSGP25L2 G	gp25L2 protein	X90872	279929
88	B4464	NTPBP	XPA binding protein 1; putative	AA075627	18259
89	B0065	MAGEB1	ATP(GTP)-binding protein	U93163	73021
90	B3907 B4446	PEPP3	melanoma antigen, family B, 1	AA913298	241161
91	N	SDR1	phosphoinositol 3-phosphite-binding protein-3	W21543	17144
92	C3741		short-chain	AK022212	118983
93	C0663	TRPM4	dehydrogenase/reductase 1	AA708532	31608
94	D6953	ZFD25	Homo sapiens cDNA FLJ12150 fis, clone MAMMA1000422	AA909999	50216
95	A3874	LILRA3	transient receptor potential cation channel, subfamily M, member 4	AF014923	113277
96	A3527	VILL	zinc finger protein (ZFD25)	D88154	103665
97	A5547	RAP1	leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3	AA434343	274428
98	A2622	MMP14	villin-like	U41078	2399
99	A4086	CKTSF1B1	TRF2-interacting telomeric RAP1 protein	AI037867	40098
100	C7949	PPP2R1A	matrix metalloproteinase 14 (membrane-inserted)	H49233	173902
101	E1852		cysteine knot superfamily 1, BMP antagonist 1	AA258620	
102	A5673	C11orf2	protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform	N24911	5258
103	A3692	TP53BPL	EST	U82939	179982
104	B8696	TP53INP1	chromosome 11 open reading frame2	AA576089	75497
105	C0318	CKB	tumor protein p53-binding protein	M16451	173724
106	A0441	FABP1	tumor protein p53 inducible nuclear protein 1	M10617	5241
107	A4035	E1B-AP5	creatine kinase, brain	AA479010	155218
108	A2490	PLOD3	fatty acid binding protein 1, liver	AF046889	153357
109	B4906	RPS15	E1B-55kDa-associated protein 5	AA526377	133230
110	A4624	CRA	procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3	U78556	166066
111	A0373	ADFP	ribosomal protein S15	X97324	3416
112	A3276	PTMS	cisplatin resistance associated	M24398	171814
113	B1939		adipose differentiation-related protein	AA663323	116897
114	C6486	HMGCS2	parathymosin	X83618	59889
115	E1825	HSPB1	EST	AW084318	76067
116	A2805	MRPL23	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial)	Z49254	3254
			heat shock 27kD protein 1		
			mitochondrial ribosomal protein		

			L23		
117	A1575	NPAS1	neuronal PAS domain protein 1	U77968	79564
118	A2373	LMNA	lamin A/C	X03444	77886
119	A0567	CSK	c-src tyrosine kinase	X59932	77793
120	A5563	C19orf3	chromosome 19 open reading frame 3	AF028824	6454
121	A4786	EZH1	enhancer of zeste (Drosophila) homolog 1	AB002386	194669
122	A9040	SLC2A1	solute carrier family 2 (facilitated glucose transporter), member 1	K03195	169902
123	A9125	CRYL1	crystalli lambda 1	N78171	108896
124	E0502		ESTs	AI240520	305172
125	A4716	HDAC3	histone deacetylase 3	U66914	279789
126	A2582	FUT4	fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)	M58596	2173
127	C4276	CELSR3	cadherin, EGF LAG seven-pass G-type receptor 3, flamingo (Drosophila) homolog	AB011536	55173
128	A8182	DPYS	dihydropyrimidinase	D78011	10755
129	C4970	ALDH1	aldehyde dehydrogenase 1, soluble	K03000	76392
130	C3752	OGDH	oxoglutarate dehydrogenase (lipoamide)	D10523	168669
131	E1606		ESTs, Moderately similar to alternatively spliced product using exon 13A [H.sapiens]	AW779971	150073
132	A0840	MYH7	myosin, heavy polypeptide 7, cardiac muscle, beta	M17712	929
133	A3945	ESR2	estrogen receptor 2 (ER beta)	AF051427	103504
134	A4556	PSMB9	proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2)	Z14977	9280
135	A5510	AXIN1	axin	AA725563	184434
136	A2644	ADH3	alcohol dehydrogenase 3 (class I), gamma polypeptide	X04299	2523
137	A5284	GPAA1	anchor attachment protein 1 (Gaa1p, yeast) homolog	AB006969	4742
138	A0094	LAMC1	laminin, gamma 1 (formerly LAMB2)	J03202	214982
139	A0897	FASTK	Fas-activated serine/threonine kinase	X86779	75087
140	A5377	TSSC1	tumor suppressing subtransferable candidate 1	AA339976	4992
141	A7226	RAGE	renal tumor antigen	U46191	104119
142	A9371		hypothetical protein FLJ23399	W45464	299883
143	C4885	KIP2	DNA-dependent protein kinase catalytic subunit-interacting protein 2	AA252866	129867
144	A9482		brain specific protein LOC51673	AI160184	279772
145	B1902	CXorf10	Chromosome X open reading frame 10	AA503892	288512

146	A9975		EST Homo sapiens cDNA FLJ13048 fis, clone NT2RP3001399, weakly similar to SSU72 PROTEIN	AA621665	208957
147	A6635		Homo sapiens mRNA; cDNA DKFZp434P228 (from clone DKFZp434P228)	AI041186	7932
148	A9233		KIAA0459 protein	W23958	108972
149	B9544		H2B histone family, member Q	AB007928	28169
150	A1460	H2BFQ	CGI-96 protein	M60756	2178
151	C7451		6-phosphogluconolactonase	AA306027	239934
152	D1418	PGLS	ESTs	AA661636	100071
153	D7200			AI268231	130829

Industrial Applicability

The expression of MLX nucleic acids of the present invention was frequently elevated in metastatic lesions compared to their corresponding primary lesions. These

5 MLX nucleic acids are predicted to be directly related to metastatic processes such as migration, vessel invasion, attachment to vessels in the liver, and/ or the growth of cancerous lesions in the metastasized environment. These genes may include not only those representing the nature of cancer cells but also genes that were affected by metastasis as secondary events, e.g., by responding to changes in the local environment (liver versus

10 colon). Future studies on their function will identify genes responsible for metastasis as well as growth in metastasized environment, and provide clues for the suppression and/or treatment of metastasis.

While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and

15 modifications can be made therein without departing from the spirit and scope of the invention.

CLAIMS

1. A method of screening for a compound for treating metastatic lesions of colorectal cancer or preventing metastasis of colorectal cancer, said method comprising the steps of:
- 5 of:
- (1) contacting a test compound with a polypeptide selected from the group consisting of:
- (a) a polypeptide comprising the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153;
- 10 (b) a polypeptide that comprises the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153, in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence encoded by the polynucleotide; and
- 15 (c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide selected from the group consisting of MLXs 1-153, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence encoded by the polynucleotide selected from the group consisting of MLXs 1-153;
- 20 (2) detecting the binding activity between the polypeptide and the test compound; and
- (3) selecting a compound that binds to the polypeptide.
2. A method of screening for a compound for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer, said method comprising the steps of:
- (1) contacting a test compound with a polypeptide selected from the group consisting of:
- 25 of:
- (a) a polypeptide comprising the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153;
- (b) a polypeptide that comprises the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153, in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a polypeptide consisting of the amino acid sequence encoded by the polynucleotide; and
- 30 (c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide selected from the group consisting of MLXs 1-153, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence encoded by the polynucleotide selected
- 35

- from the group consisting of MLXs 1-153;
- (2) detecting the biological activity of the polypeptide of step (a); and
 - (3) selecting a compound that suppresses the biological activity of the polypeptide in comparison with the biological activity detected in the absence of the test compound.
- 5 3. A method of screening for a compound for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer, said method comprising the steps of:
- (1) contacting a test compound with a cell expressing one or more marker genes, wherein the marker genes are selected from the group consisting of MLXs 1-153; and
 - (2) selecting a compound that reduces the expression level of one or more of the
- 10 marker genes.
4. The method of claim 3, wherein said cell expressing one or more marker genes comprises a colorectal cancer cell.
5. A method of screening for a compound for treating colorectal cancer or preventing metastasis of colorectal cancer, said method comprising the steps of:
- 15 (1) constructing a vector comprising the transcriptional regulatory region of a gene selected from the group consisting of MLXs 1-153 upstream of a reporter gene;
- (2) transforming a cell with the vector of step (1);
 - (3) contacting a test compound with the cell of step (2);
 - (4) detecting the expression of the reporter gene; and
- 20 (5) selecting the test compound that suppresses the expression of the reporter gene compared to that in the absence of the test compound.
6. A kit comprising one or more detection reagents that respectively binds to one or more nucleic acid sequences selected from the group consisting of MLXs 1-153.
7. An array comprising one or more nucleic acids that respectively binds to one or more
- 25 nucleic acid sequences selected from the group consisting of MLXs 1-153.
8. A method for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer, said method comprising the step of administering a pharmaceutically effective amount of a compound that is obtained by the method according to any one of claims 1-5.
- 30 9. A method for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer in a subject, said method comprising the step of administering to the subject a pharmaceutically effective amount of an antisense nucleic acids or small interference RNA against one or more genes selected from the group consisting of MLXs 1-153.
- 35 10. A method for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer in a subject, said method comprising the step of administering to the

subject a pharmaceutically effective amount of an antibody or fragment thereof that binds to a protein encoded by a gene selected from the group consisting of MLXs 1-153.

11. A method for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer in a subject, said method comprising the step of administering to the subject a pharmaceutically effective amount of a polypeptide selected from the group consisting of (a)-(c), a polynucleotide encoding the polypeptide or a vector comprising the polynucleotide encoding the polypeptide:

(a) a polypeptide comprising the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153 or fragment thereof;

(b) a polypeptide that comprises the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153, in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence encoded by the polynucleotide or fragment thereof; and

(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide selected from the group consisting of MLXs 1-153, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence encoded by the polynucleotide selected from the group consisting of MLXs 1-153 or fragment thereof.

12. A method for inducing an anti-tumor immunity, said method comprising the step of contacting with an antigen presenting cell a polypeptide selected from the group consisting of (a)-(c), or a polynucleotide encoding the polypeptide or a vector comprising the polynucleotide:

(a) selected from the group consisting of MLXs 1-153 or fragment thereof;

(b) a polypeptide that comprises the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153, in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence encoded by the polynucleotide or fragment thereof; and

(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide selected from the group consisting of MLXs 1-153, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence encoded by the polynucleotide selected from the group consisting of MLXs 1-153 or fragment thereof.

13. The method for inducing an anti-tumor immunity of claim 12, wherein the method further comprises the step of administering the antigen presenting cell to a subject.

14. A composition for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer in a subject, said composition comprising a pharmaceutically effective amount of a compound that is obtained by the method according to any one of claims 1-5.
- 5 15. A composition for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer in a subject, said composition comprising a pharmaceutically effective amount of an antisense nucleic acids or small interference RNA against one or more genes selected from the group consisting of MLXs 1-153.
- 10 16. A composition for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer in a subject, said composition comprising a pharmaceutically effective amount of an antibody or fragment thereof that binds to a protein encoded by a gene selected from the group consisting of MLXs 1-153.
- 15 17. A composition for treating metastatic lesion of colorectal cancer or preventing metastasis of colorectal cancer in a subject, said composition comprising a pharmaceutically effective amount of a polypeptide selected from the group consisting of (a)-(c), a polynucleotide encoding the polypeptide or a vector comprising the polynucleotide:
- (a) a polypeptide comprising the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153 or fragment thereof;
 - 20 (b) a polypeptide that comprises the amino acid sequence encoded by a polynucleotide selected from the group consisting of MLXs 1-153, in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence encoded by the polynucleotide or fragment thereof; and
 - 25 (c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide selected from the group consisting of MLXs 1-153, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence encoded by the polynucleotide selected from the group consisting of MLXs 1-153 or fragment thereof.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031775 A3

(51) International Patent Classification⁷: **G01N 33/574**,
C12Q 1/68, C12N 15/11, C07K 14/47, A61K 39/00, A61P
35/04, C07K 16/30

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/JP2003/010339

Declarations under Rule 4.17:

(22) International Filing Date: 14 August 2003 (14.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/414,709 30 September 2002 (30.09.2002) US

(71) Applicants (for all designated States except US): **ON-
COTHERAPY SCIENCE, INC.** [JP/JP]; 3-16-13,
Shirokanedai, Minato-ku, Tokyo 108-0071 (JP). **JAPAN
AS REPRESENTED BY THE PRESIDENT OF
THE UNIVERSITY OF TOKYO** [JP/JP]; 3-1, Hongo
7-chome, Bunkyo-ku, Tokyo 113-8654 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NAKAMURA,**
Yusuke [JP/JP]; 17-33, Azamino 1-chome, Aoba-ku,
Yokohama-shi, Kanagawa 225-0011 (JP). **FURUKAWA,**
Yoichi [JP/JP]; 10-40, Miyazaki 3-chome, Miyamae-ku,
Kawasaki-shi, Kanagawa 216-0033 (JP).

(74) Agents: **SHIMIZU, Hatsushi** et al.; Kantetsu Tsukuba
Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki 300-
0847 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
14 October 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR TREATING OR PREVENTING METASTASIS OF COLORECTAL CANCERS

(57) Abstract: Disclosed are methods of identifying agents for treating metastatic lesions of colorectal cancer. Also disclosed are methods for treating metastatic lesions of colorectal cancer and preventing metastasis of colorectal cancer.

WO 2004/031775 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 03/10339

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/574 C12Q1/68 C12N15/11 C07K14/47 A61K39/00
 A61P35/04 C07K16/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ZEMBUTSU H ET AL: "Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 62, no. 2, 15 January 2002 (2002-01-15), pages 518-527, XP002224797 ISSN: 0008-5472 Abstract; Table 2-Continuation at p. 523.	1-5, 11, 17
X	WO 02/21996 A (EOS BIOTECHNOLOGY INC ; GISH KURT C (US); MACK DAVID H (US); WILSON) 21 March 2002 (2002-03-21) Paragraph 6, 7, 24 and 25; Tables 1 and 2; Claims 1-31.	1-5, 11, 17

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the International search

17 March 2004

Date of mailing of the International search report

13.08.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Lopez García, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 03/10339

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SNYDER STEVEN R ET AL: "Identification of CCAAT displacement protein (CDP/cut) as a locus-specific repressor of major histocompatibility complex gene expression in human tumor cells"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 7, 16 February 2001 (2001-02-16), pages 5323-5330, XP002273064</p> <p>ISSN: 0021-9258</p> <p>Abstract; p. 5329, last paragraph.</p>	1-5,11, 17
X	<p>YANAGAWA R ET AL: "IDENTIFICATION OF GENES ASSOCIATED WITH LIVER METASTASIS OF COLORECTAL CANCER BY MEANS OF CDNA MICROARRAY"</p> <p>PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, 24 March 2001 (2001-03-24), page 59, XP001157334</p> <p>ISSN: 0197-016X</p> <p>the whole document</p>	1-5,11, 17
X	<p>YANAGAWA R ET AL: "GENOME-WIDE SCREENING OF GENES SHOWING ALTERED EXPRESSION IN LIVER METASTASES OF HUMAN COLORECTAL CANCERS BY CDNA MICROARRAY"</p> <p>NEOPLASIA, DOYMA, BARCELONA,, ES, vol. 3, no. 5, September 2001 (2001-09), pages 395-401, XP009024057</p> <p>ISSN: 0212-9787</p> <p>cited in the application abstract</p>	1-5,11, 17
A	<p>NIRODI C ET AL: "The role of CDP in the negative regulation of CXCL1 gene expression"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 28, 13 July 2001 (2001-07-13), pages 26122-26131, XP002221614</p> <p>ISSN: 0021-9258</p> <p>abstract</p>	1-5,11, 17
T	<p>LI MEIHUA ET AL: "Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray."</p> <p>INTERNATIONAL JOURNAL OF ONCOLOGY. GREECE FEB 2004, vol. 24, no. 2, February 2004 (2004-02), pages 305-312, XP009027443</p> <p>ISSN: 1019-6439</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/10339

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0221996	A	21-03-2002	US 2003077568 A1	24-04-2003
			AU 9090201 A	26-03-2002
			CA 2422278 A1	21-03-2002
			EP 1317669 A2	11-06-2003
			JP 2004515225 T	27-05-2004
			WO 0221996 A2	21-03-2002
			US 2002102544 A1	01-08-2002
<hr/>				

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 03/10339

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-13 (PARTIALLY)
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 6, 8, 12, 13, 14
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5, 11 and 17 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 8-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 8-13 (PARTIALLY)

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 6, 8, 12, 13, 14

Present claims 6 refers to reagents that bind to the nucleic acids MLXs 1-153 without giving a true technical characterization. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not found in the application. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Present claims 8 and 14 refer to methods of treatment using "compounds obtained by the methods according to any of the claims 1-5" and to compositions comprising the "compounds obtained by the methods according to any of the claims 1-5" without giving a true technical characterization. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not found in the application. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Present claims 12-13 which do not contain any technical feature to characterize a "method for inducing an anti-tumor immunity" so lack clarity (Art. 6 PCT) and support in the description (Art. 5 PCT) that no meaningful search can be carried out (Art. 6 PCT).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.